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Developing effective therapeutic strategies for gliomas, a type of primary brain 
tumor, is one of the current focuses in cancer therapy. Gene therapy, while 
still at the stage of preclinical and clinical trials, has shown promise for 
therapeutic intervention of gliomas. To be effective, however, gene therapy 
requires gene transfer vehicles capable of efficiently transducing tumor cells. 
The research conducted for this thesis focused mainly on strategic 
development of gene transfer vectors with the objective of boosting gene 
delivery performance in glioma cells and potentially improving on current 
therapies for central nervous system (CNS) glioma tumors. 
 
Non-viral magnetofection facilitates gene transfer by using a magnetic field to 
concentrate magnetic nanoparticle-associated plasmid delivery vectors onto 
target cells. In light of the well-established effects of the transactivating 
transcriptional activator (Tat) peptide, a cationic cell-penetrating peptide, in 
enhancing the cytoplasmic delivery of a variety of cargos, we tested whether 
the combined use of magnetofection and Tat-mediated intracellular delivery 
would improve transfection efficiency. Through electrostatic interaction, bio-
nanoparticles were formed by mixing polyethyleneimine (PEI)-coated cationic 
magnetic iron beads with plasmid DNA, followed by the addition of a 
bis(cysteinyl) histidine-rich Tat peptide. These ternary magnetofection 
complexes provided a four-fold improvement in transgene expression over the 
binary complexes without the Tat peptide, and transfected up to 60% of cells 
in vitro. Enhanced transfection efficiency was also observed in vivo in the rat 
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spinal cord after lumbar intrathecal injection. Moreover, the injected ternary 
magnetofection complexes in the cerebrospinal fluid responded to a moving 
magnetic field by shifting away from the injection site and mediating transgene 
expression in a remote region. Thus, bio-nanoparticles could potentially be 
useful for effective gene therapy treatments of localized diseases. 
 
Insect baculovirus (BV)-based vectors were recently introduced as potential 
viral gene delivery vectors to overcome obstacles inherent in commonly used 
animal viral systems. Upon in vivo administration, however, BVs are easily 
inactivated following exposure to serum complements. We hypothesized that 
the problems of serum inactivation could be avoided by assembling bio-
nanoparticles through the interaction of PEI-coated cationic magnetic iron 
beads, Tat peptide, and therapeutic BVs, rather than plasmid DNA. Our 
preliminary in vitro studies indicate positive results. 
 
More importantly, our studies show that BV particles can be encapsulated 
inside bio-microfibers, which may offer an innovative material engineering 
approach to protecting BVs against serum complement inactivation. We 
established the generation of fibers through self-assembly of polyelectrolytes 
comprising plasmid DNA and a set of specially designed amphiphilic peptides 
of alternating Leucine, Alanine, and Arginine residues. The positively charged 
Arginine peptide units can interface with plasmid DNA through electrostatic 
interactions. Additionally, the hydrophobic nature of Leucine and Alanine 
strengthens the connections between peptide molecules, thus facilitating fiber 
formation at high concentrations. Our findings suggest that BVs retain their 
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activity after emerging in the fiber, and the fibers provide a sustained release 
of the BV over a period of 48 hours by inducing sufficient transgene 
expressions in a glioma cell line. Of particular note is that BVs encapsulated 
inside the fiber have shown resistance to human serum complement both in 
vitro and in vivo, which indicates a promising opportunity to protect BVs 
against serum inactivation during systemic administration. 
 
In summary, we have devised and implemented a strategy to use 
complexation procedures to form bio-nanoparticles and bio-microfibers. The 
findings in this study should enrich the development of gene therapies for 
CNS diseases, particularly in glioma tumors, and should advance virus, 
material engineering, and gene delivery-related studies. 
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1.1 General Introduction 
Gliomas are a type of primary central nervous system (CNS) tumor that arise 
from glial cells and have a tendency to aggressively invade the brain. Gliomas 
originate predominantly from astrocytes, and are graded from I to IV with 
increasing level of malignancy. Grade IV gliomas, also termed glioblastoma 
multiforme, comprise nearly half of all gliomas and are the most frequent 
primary brain tumors in adults. Even with complete surgical excision, radiation 
therapy, and chemotherapy, high-grade gliomas almost always grow back and 
patients usually die within a year, with only a few patients surviving longer 
than 3 years (Ohgaki et al., 2004; Ohgaki and Kleihues, 2005). In this study, 
we proposed to adopt gene therapy with both viral and non-viral vectors and 
putative anti-tumor genes that have been used successfully for other cancers, 
along with various gene regulatory elements, to treat gliomas. 
 
1.1.1 Introduction to Gene Therapy 
Gene therapy is a disease treatment that involves the addition into an 
individual’s cells of foreign genetic materials that reconstitute or correct 
missing or aberrant genetic functions or interfere with disease-causing 
processes. In the case of a hereditary disorder, the gene therapy will replace 
a defective mutant allele with a functional one (Factor, 2001). On September 
14, 1990, the first approved gene therapy procedure was performed by 
Brandon Rogers at the U.S. National Institutes of Health on a 4-year old 
patient born with severe combined immunodeficiency, a rare genetic disease 
that made her extremely vulnerable to infections. White blood cells from the 




inserted and the white blood cells were then infused back into the patient’s 
bloodstream. The genetically modified cells functioned for a few months and 
then the process had to be repeated. Laboratory tests showed that the 
genetically modified blood cells strengthened the patient’s immune system; 
she no longer suffers recurrent colds, she has been allowed to attend school, 
and she was immunized against whooping cough. Gene therapy is one of the 
most rapidly advancing fields in biotechnology, with hundreds of clinical trials 
underway worldwide (Verma and Somia, 1997). Accelerated by recent 
scientific breakthroughs in genomics and an understanding of the important 
role of genes in disease, gene therapy holds great promise for treating both 
inherited and acquired diseases. 
 
Gene therapy involves three essential components: a therapeutic gene; a 
regulatory element, usually a promoter; and a delivery vehicle, also known as 
a vector (Russell, 1997). Therefore, three central issues have emerged as this 
technology advances: gene identification, gene expression, and gene delivery. 
The therapeutic gene is selected according to the target disease. Originally, 
the therapeutic gene was used as a substitute for the mutant gene. However, 
this replacement was complex and difficult in the disease-treating process. 
The therapeutic gene is now more commonly and practically used to alleviate 
diseases, either inherited or acquired, by enhancing, reducing, or altering a 
particular gene expression in the target cells (Mountain, 2000). Therapeutic 
genes must be controlled by a regulatory element, usually a promoter that is 
functionally active in the respective cell type. The expression level and 




promoter at the transcriptional level, and the type of promoter can also 
influence the duration of transgene expression. The gene delivery vector, 
which carries and transfers the gene of interest into the nuclei of the host cell 
as part of its replication cycle, is another key player in gene therapy. The 
tropism of the vector can essentially decide the cell type specificity of the 
transgene expression at the transductional level, and the transduction 
efficiency of the vector will largely determine the expression level. More 
importantly, the status of the transferred gene—integrated or episomal—will 
decide the transient or long-term duration of the transgene expression. For 
glioma gene therapy, both the promoter and vector must be carefully selected, 
combined, and sometimes properly modified for the treatment of a particular 
condition. 
 
1.1.2 Overview of Gene Delivery Vectors 
Potential gene transfer vectors for mammalian cells are classified into 
physical, non-viral, and viral vectors. Physical delivery modalities, such as 
needle-free injection, which is often referred to as “gene gun” or “Jetgun,” 
make use of high-pressure power to deliver DNA. Electroporation, which 
transfers DNA to cells using an electric field to transiently break down the cell 
membrane, has been used for many years (Mathei et al., 1997; Tacket et al., 
1999). However, due to their poor in vivo performance and low efficiency, 
physical vectors are not extensively employed for gene therapy applications 





Non-viral and viral vectors are the most common gene delivery vehicles. 
Numerous studies have demonstrated the capability of non-viral materials 
such as cationic polymers, lipids, proteins, and peptides as vectors to mediate 
gene delivery (Lungwitz et al., 2005; Martin et al., 2005; Gupta et al., 2005). 
The advantages of a non-viral system, including ease of manipulation, 
delivery flexibility, large transfer capacity, and low pathogenic risk, have made 
it an attractive research area. However, this system has the drawback of low 
transfection efficiency. 
 
On the other hand, viral vectors can achieve high transduction efficiencies 
that seem unreachable for non-viral gene delivery systems. Six main types of 
viral vectors have been developed for CNS gene delivery purposes. 
(1) Herpes simplex virus (HSV) type 1, a common human pathogen carrying a 
double-stranded DNA of 152 kb, has a high infectivity in neurons, glial cells, 
and several other cell types. HSV type 1 can be delivered by rapid retrograde 
transport along neurites to the cell body (Bearer et al., 1999; Sodeik et al., 
1997), offering a means of targeted gene transfer to neuronal cells that is 
otherwise difficult to reach. However, the cytotoxicity and short-term gene 
expression mediated by HSV type 1 has hampered its application for gene 
therapy of CNS disorders. (2) Adeno-associated virus (AAV) is a non-
pathogenic small virus that contains a single-stranded DNA genome. AAV-
based vectors can transfer a 4.5 kb transgene to host cells (Muzyczka, 1992), 
and inverted terminal repeat elements in the AAV genome can promote 
random or site-specific extra-chromosomal replication and genomic 




1990; Walther and Stein, 2000; Weitzman et al., 1994; Yang et al., 1997) of 
the transgene (Xiao et al., 1997), providing an opportunity to achieve 
sustainable expression of foreign genes. The drawbacks of AAV as a gene 
delivery vector are its small packaging capacity and the inconvenience of 
large-scale preparation of viral stock (Rabinowtz and Samulski, 1998). 
(3) Adenovirus is another well-established gene delivery vector. Initially, the 
replication-defective adenovirus vectors had limitations for gene therapy 
because of a strong host immune response to the viral antigens (Dai et al., 
1995; Yang et al., 1994). Recently, high-capacity “gutless” or “mini-
chromosome” adenovirus vectors have been developed that retain only the 
sequences necessary for packaging and replication of the viral genome, but 
lack all structural genes (Fisher et al., 1996; Hardy et al., 1997; Kochanek et 
al., 1996). These modified vectors have shown increased transgene cloning 
capacity and safer high-titer propagation methods by means of a Cre-lox-
based recombinase system instead of helper adenovirus (Hardy et al., 1997). 
In vivo studies have indicated prolonged expression of transgenes delivered 
by these vectors, with less host inflammatory response (Kumar-Singh and 
Farber, 1998; Lieber et al., 1997; Morsy et al., 1998). Despite the fact that 
new generations of adenoviruses have been created with decreased toxicity 
profiles in animals, the fatality report from an E1/E4-deleted adenovirus 
infused into the hepatic artery of a young man with partial ornithine 
transcarbamylase deficiency has become a severe obstacle in the application 
of adenoviruses for human gene therapy (Lusky et al., 1998; Schiedner et al., 
1998; Raper et al., 2003). (4) Retrovirus vectors, derived primarily from 




that can transfer genes to a wide range of dividing cell types. Retrovirus 
vectors can mediate long-term gene expression by chromosomal integration 
and are well suited for on-site delivery to neural precursors for lineage studies 
(Cepko et al., 2000), to tumor cells for therapeutic intervention, and for ex vivo 
gene transfer. The use of retrovirus vectors for gene delivery to the CNS, 
however, has been hampered by their ability to activate some pro-oncogenes 
by random insertion (VandenDriessche et al., 2003). Moreover, their inability 
to infect non-dividing cells and the possibility of causing immunodeficiency 
has also restricted the application of retrovirus vectors for gene delivery to the 
CNS (Coffin et al., 2000). (5) Lentivirus is a well-known member of the 
retrovirus family. Lentivirus-based vectors have the potential to integrate into 
the host genome of both dividing and non-dividing cells, establishing the 
possibility of developing a delivery system with stable expression even in 
postmitotic neurons (Naldini et al., 1996). The limited host range, low titers, 
and pathogenic characteristics of the vector itself, however, hinder its utility as 
a gene delivery system for the CNS. (6) Baculovirus (BV) is a type of large, 
rod-shaped virus that belongs to the Baculoviridae family. Accumulated 
reports have demonstrated that a wide spectrum of cells and tissues are 
susceptible to BV infection, resulting in relatively high transgene expression 
levels and suggesting the strong potential of BV vectors in gene delivery, 
which will be used to establish proof of concept in the proposed study and 





1.1.2.1 Polyethylenimine as a Powerful Non-viral Vector 
Polyethylenimine (PEI), a type of cationic polymer and one of the most 
commonly used non-viral vectors, has demonstrated high transfection 
efficiency in both in vitro and in vivo gene transfer studies (Abdallah et al., 
1996a; Boussif et al., 1995; Goula et al., 1998). PEI can be linear or branched. 
The branched form is synthesized by cationic polymerization from aziridine 
monomers via a chain-growth mechanism. The linear form of PEI also 
originates from cationic polymerization, but from a 2-substituted 2-oxazoline 
monomer instead. The product is then hydrolyzed to yield linearized PEI 
(Godbey et al., 1999). Because PEI polymers are able to effectively complex 
even large DNA molecules (Campeau et al., 2001), they mediate transfection 
by condensing DNA into homogeneous spherical nanoparticles or PEI/DNA 
complexes of 100 nm or less. This protects DNA from enzymatic degradation 
and facilitates cell uptake and endolysosomal escape of the PEI/DNA 
complex, thereby enabling efficient cell transfection in vitro as well as in vivo. 
The branched form of PEI can achieve much higher cell transfection efficiency 
than does linear PEI, and has therefore attracted considerable attention for 
gene delivery to mammalian cells. The most frequently used gene delivery 
vehicle is highly branched PEI with the molecular weight of 25 kDa (Fischer et 
al., 1999). Gene delivery into primary central and peripheral neurons has 
been successfully realized by antisense oligonucleotide shuffles conjugated to 
PEI (Lambert et al., 1996). Moreover, the in vivo transfection capability of PEI 
was documented when gene expressions were detected in mature mouse 
brain by using PEI/DNA complex with PEI of different molecular weights 





1.1.2.2 Baculovirus-mediated Gene Transfer 
BVs constitute a group of double-stranded DNA viruses that cause lethal 
diseases in arthropods. A member of the BV family, Autographa californica 
multiple nucleopolyhedrovirus (AcMNPV)-based vectors were recently 
recognized as a type of promising viral gene delivery vectors. This AcMNPV 
BV is a large enveloped virus with a double-stranded, circular DNA genome of 
~130 kb (Ayres et al., 1994). The viral envelope protein GP64 interacts with 
cell surface molecules to facilitate BV uptake. Following receptor binding, the 
BV is transported into the cytoplasm via endolysosomal maturation and 
endosomal escape, after which the BV capsids are carried to the nuclear pore 
with the assistance of actin filaments. They are then transferred through the 
nuclear pore into the nuclear lumen to carry out the subsequent gene 
expression functionality (van Loo et al., 2001). Studies have shown that 
recombinant vectors derived from this BV can efficiently transduce a variety of 
cell types, such as hepatic, pancreatic, kidney, and neural cells from different 
species including rodents, primates, and humans. High expression levels of 
the delivered genes were readily detected after successful transductions 
(Boyce and Bucher, 1996; Condreay et al., 1999; Sarkis et al., 2000). These 
observations revealed that recombinant BV could be a powerful vector with 
application for various types of gene therapies. BVs are non-replicative in 
mammalian cells, making the gene deliveries mediated by BV vectors 
controllable. The large DNA size of BV provides large cloning capacity. In 
addition, production and manipulation processes of recombinant BVs are 




2002; Kost and Condreay, 2002). Furthermore, the lack of obvious 
pathogenicity and the inability to express any viral gene in mammalian cells 
make BV the safest viral vector for humans. These intrinsic advantages 
highlight BV vectors as a very enabling technology for various gene delivery 
applications. 
 
Despite encouraging transduction performance achieved by BV vectors, 
certain problems remain. Recombinant BV performance in gene deliveries is 
promoter dependent to a large extent. Highly active promoters are necessary 
to ensure the transgene expressions of recombinant BV vectors engineered to 
deliver genes of interest to mammalian cells and tissues. Strong promoters 
derived from infective viruses, such as cytomegalovirus (CMV), simian virus, 
and CMV enhancer/chicken β-actin promoter (CAG), have been commonly 
used. As a result of the relative uncontrollability of such strong promoters, a 
wide range of cells and tissues will be affected when subjected to such 
recombinant BV transduction. Furthermore, the application of BV in clinical 
gene therapy could be obstructed by unspecific side effects, including 
possible immune responses and complement attack. Hence, engineered 
recombinant BV vectors equipped with suitable targeting apparatus are highly 
desired to realize the specific delivery and expression of the transgene in 
target cells, while minimizing unspecific transgene expression. 
 
Another major disadvantage of BV as a gene delivery vector is its poor in vivo 
delivery performance in the CNS, which is considered an immune privileged 




al., 2004; Kost and Condreay, 2002; Li et al., 2005; Sandig et al., 1996) due to 
the vulnerability of BV in the presence of serum factors (Hofmann et al., 1998; 
Hofmann et al., 1999). The susceptibility of BV to inactivation by complement 
exposure possibly resulted from the fact that BV, derived from insects, was 
not subjected to the human complement system during evolution. As a result, 
BV did not evolve a defensive mechanism to tolerate an attack from the 
human complement system (Hofmann et al., 1999; Kost and Condreay, 2002; 
Sandig et al., 1996; Hofmann et al., 1998). Virus particle surface modification 
is one of the effective strategies to enhance BV’s in vivo gene delivery 
performance. Previous reports show that the surface display method can be 
used to improve BV resistance to serum complement inactivation (Hüser et al., 
2001). However, complicated cloning work is required for such biological 
modifications. In addition, BV production yield is restricted by adding foreign 
protein sequences on the surface, making it extremely difficult to obtain BV 
solutions with titers high enough for in vivo study. Effective and flexible 
modification approaches are still required to overcome the problem of serum 
complement inactivation. 
 
A main limitation of BV-mediated transgene expression is its short expression 
period, which is particularly unsuitable for gene therapy of CNS glioma (Kost 
and Condreay, 2002). Raymond performed the first detailed analysis of BV 
integrants within mammalian cells, highlighting the importance of considering 
long-term transgene stability, especially for studies designed to correct 
genetic defects in vivo (Merrihew et al., 2001). Studies using periodic assays 




expression for at least two of the clones. These results strengthened the 
potential application of BV to deliver single copies of stably integrated genes 
into mammalian genomes. Since the illegitimate mode of integration and long-
term stability of reporter gene expression is similar to that observed for 
transfected DNA and other viruses, recombinant BVs should provide a 
superior alternative for DNA transfer into mammalian cells. Indeed, in recent 
studies with several different cell lines, stable clones have already been 
obtained from any cell line that is successfully transduced transiently, 
independent of the transduction efficiency. 
 
Another concern is that preparing large volumes of high-titer vectors is time-
consuming and laborious. Producing BV particles is relatively simple in 
comparison with other types of viral vectors, such as lentivirus, which requires 
co-transfection of a set of plasmids for each batch of virus production, or AAV, 
which requires a complicated process for purification. Nevertheless, the large-
scale production of high-quality BV particles is necessary when they are used 
as gene delivery vectors, especially for in vivo application. Hence, feasible 
purification and concentration methods need to be established to facilitate 
large-scale preparation of BV particles, while minimizing the detrimental effect 
on virus bioactivity. 
 
Little is known about the transduction mechanisms of BVs in mammalian cells. 
Several investigators have demonstrated the pathways of BV entry and 
transduction with different mammalian cell lines, yet the studies show 




vary for different cell types. It is generally assumed that the escape from the 
endosomes blocks the BV transduction of some mammalian cells. However, 
the detailed mechanisms of intracellular movement and nuclear entry of the 
virus are still largely unknown. Moreover, to devise and optimize experimental 
treatment strategies, researchers need a method to non-invasively assess BV 
delivery to the target cells or tissues of interest using experimentally and 
clinically relevant imaging methodologies. At present, reports of in vivo 
imaging of BV in target tissues are limited to bioluminescence imaging. BV 
capsid display, which fuses enhanced GFP (EGFP) into the N-terminus or C-
terminus of the major capsid protein vp39, offers a useful tool for transduction 
imaging. Yet tiring cloning work is still required for such applications. 
Therefore, it is imperative to develop a novel transduction imaging technology 
that efficiently reveals the transduction route of BV in mammalian cells to 
allow researchers to follow or even modify the intracellular fate of BV and also 
monitor BV-mediated gene delivery in a relevant clinical context. 
 
1.1.2.3 Nanoparticle-mediated Gene Delivery 
Drug and gene delivery have traditionally been achieved through oral or 
intravenous routes, both of which are inefficient, non-specific, and expensive. 
Innovative gene delivery approaches have recently been inspired by new 
findings in the field of nanotechnology. Non-viral gene delivery vectors have 
drawn increasingly more attention due to their ability to overcome the safety 
issues of their viral counterparts. Nanoparticles are one of the most well 
studied non-viral gene delivery vectors because of their attractive 




to change their surface properties. Nanoparticles offer numerous advantages 
to promote gene transfection efficiency compared with other gene delivery 
systems. Gold, carbon nanotubes, fullerenes, layered double hydroxides 
(LDH), biodegradable nanoparticles made from biocompatible polymers such 
as poly(D,L-lactide-co-glycolide) (PLGA) or polylactide (PLA), and several 
oxide nanoparticles have all been used to facilitate cellular delivery of 
therapeutic genes. Nanoparticles enable much greater control over the 
delivery process, targeting to specific tissues or even some specific cell types 
with higher stability and delivery efficiency. This merit allows for lower gene or 
drug dosing to avoid cytotoxicity. Moreover, nanoparticles can be fabricated in 
large quantities at lower cost. Nanoparticles composed of natural polymers 
are desired over synthetic ones because of their greater biocompatibility and 
biodegradability. 
 
Nanoparticles offer significant promise as efficient non-viral gene delivery 
vectors. In one study, functionalized nanoparticles of calcium phosphate were 
synthesized by controlled precipitation from aqueous solution followed by 
DNA coating and transfecting human endothelial cells. The results showed 
that nanoparticles are capable of transferring DNA into the nucleus of 
transformed human endothelial cells (T. Welzel et al., 2004). Another study 
demonstrated that modified gold nanoparticles with thiolated oligonucleotides 
can be used as effective non-viral DNA delivery vectors (Jen et al., 2004). 
Internalization of LDH nanoparticles into cells has also been reported, and 
great progress has been made in developing LDH nanoparticles as efficient 




al., 2009). In most cases, nanoparticle-mediated gene delivery offers rapid 
transfection and, as indicated by more recent work, excellent overall 
transfection levels. Attaching the gene of interest to nanoparticles may 
improve both uptake by cells and the escape of the particles from lysosomes, 
which typically degrade gene carriers and prevent them from delivering their 
DNA payload to the cell nucleus, the target site for gene therapy.  
 
1.1.3 Introduction to Self-assembled Polyelectrolyte Microfibers 
1.1.3.1 Mechanism of Microfiber Formation 
To understand the principles of this work, it is crucial to explain in detail the 
self-assembly approach, defined as an integration process in which the 
components assemble in a spontaneous manner, usually by bouncing around 
in a solution or gas phase until a steady architecture of minimum energy is 
reached. Self-assembly is one of the most important methods for the 
assembly of biological molecules, and is thus a promising method for 
integrating and precisely engineering macromolecules such as proteins and 
nuclear DNA as well as biological particles such as viruses. In nature, one the 
most fundamental examples of biomolecular self-assembly occurs when two 
single strands of DNA assemble into the infamous double helix, where base 
pairing allows the specific assembly of the double helix to be stabilized by 
relatively strong hydrophobic interactions between the aromatic bases within 
the center of the helix. Components in self-assembled structures are 
automatically located to their specific sites based only on their structural 
properties, physical properties, or chemical properties, in the case of atomic 




nanoscale molecules and can be achieved on almost any scale, where the 
powerful bottom-up approach is frequently used to construct macro and nano 
structures of biological functions from molecular building blocks (Tu and Tirrell, 
2004; Zhang, 2003). Self-assembled macromolecules use proteins and 
nuclear DNA as their building blocks. The advantage of the bottom-up design 
is that the interactions holding together a single component—such as covalent 
bonds, van der Waals forces, and electrostatic interactions—are far stronger 
than the weak interactions that hold more than one molecule together. 
 
One promising approach to forming self-assembled structures is to attach 
single-stranded DNA encoding biological information to the small particles that 
one wishes to assemble. These components could range from diamondoid 
manifolds to metallic clusters that function as quantum dots. DNA stores 
genetic information, but is not known to play any structural roles and is 
therefore unlikely to interfere with the final structure. However, the precise 
base-pairing of nucleic acids offers the possibility of programmable self-
assembly in two and three dimensions. In addition, DNA can be coupled to 
other materials to allow controllable and thermally reversible assembly over a 
range of length scales (Payne, 2007). Upon receiving an external stimulus, 
these self-assembly systems will spontaneously bring together biomimetic 
arrangement with biological functionalities and organized structural properties. 
It is a challenging task, however, to design small particles or molecules that 
hold together biologically meaningful components without losing their 
biological functions. The ultimate objective is to associate components of 




Clearly, success with this approach would have huge impacts on applications 
in material science, nanotechnology, and bioengineering. 
 
Amphiphilic peptides comprising alternating hydrophobic and hydrophilic 
blocks are another commonly used raw material to form self-assembly 
structures. Alanine and Leucine amino acids are often recruited as 
hydrophobic domains, while Lysine and Arginine are regularly used as the 
hydrophilic counterparts. Depending on the alignment of these building blocks 
in the sequence and also the surfactant number, various self-assembled 
formations can be realized (Hartgerink et al., 2002; Fairman and Åkerfeldt, 
2005), such as micelles (Yim et al., 2006), nano and microfilaments 
(Papapostolou et al., 2007), and hydrogels (van den Beucken et al., 2006). 
 
There are certain forces responsible for the self-assembly formation and 
stability of biomolecules: hydrophobic interaction, electrostatic attraction and 
hydrogen bonding, specific protein-ligand interactions, and other non-bonding 
interactions. Hydrophobic interaction is caused by the tendency of 
hydrocarbons (or of lipophilic hydrocarbon-like groups in solutes) to shape 
intermolecular aggregates in an aqueous solution, and analogous 
intramolecular interactions. Amphiphilic molecules composed of both 
hydrophilic and hydrophobic subunits have been extensively exploited in a 
variety of self-assembled formations. Hydrophobic interaction leads to a 
facilitation of surfactant self-assembly that could cause, for example, a 
decrease of the critical micelle concentration. In this case it would be more 




to self-associate. The main driving force behind hydrophobic interactions is 
phase separation phenomena that contribute to the apparent repulsion 
between water and hydrocarbons. Hydrophobic interactions are often used for 
the assembly of supramolecules. For example, the natural concavity of 
cyclodextrins and cyclophanes can be employed to build inclusion complexes. 
In fact, the hydrophobic nature of their inner cavities can segregate apolar 
foreign molecules from the surrounding aqueous medium. 
 
Electrostatic attraction is the attraction that holds two oppositely electrical-
charged bodies together. Back in the 1990s, it had been conjectured that 
electrostatic interactions could act as an important basis for innovative self-
assembly mechanisms. Electrostatic self-assembly can be manipulated, but 
requires two elements for this formation to work. The first element is a pair of 
oppositely charged colloids or macromolecules. It is possible to create a 
polymeric chain that carries electrostatic charges along its backbone. These 
chains—or polyelectrolytes—exhibit high solubility in water. Another 
characteristic is their strong adsorbing capacity on surfaces bearing an 
opposite charge. The second element of the pair is an oppositely charged 
nanometer-sized colloid. For example, Harada and Kataoka used a small and 
bulky protein, the chicken egg white lysozyme (diameter 5 nm), and Bronich 
used a surfactant micelle (Harada and Kataoka, 1998; Bronich et al., 1997). 
The self-assembly process by electrostatic interaction simply requires soaking 
a selected substrate in alternate aqueous solutions containing anionic and 
cationic materials, such as complexes of polymers, metal and oxide 




other biomolecules. Patterning these individual precursor molecules and 
controlling the order of the multiple molecular layers through the thickness of 
the film or fibers allows for manipulation of the macroscopic electrical, optical, 
magnetic, thermal, mechanical, and other properties relevant to many 
engineering and medical applications. The fundamental principle of 
electrostatic interactions is simple: two oppositely charged particles, 
suspended in a fluid, will be attracted to each other. It is often most 
convenient to generate charged microstructures using self-assembled 
monolayers (Krupp et al., 1967; Maboudian and Howe, 1997). Electrostatic 
interactions have a longer range than hydrophobic or hydrogen-bonding 
interactions, and assemblies formed electrostatically can theoretically form by 
attraction of particles over substantial distances.  
 
A hydrogen bond is defined as the appealing force between one 
electronegative atom and a hydrogen atom covalently connected to another 
electronegative atom. The connection is caused by a dipole-dipole force with 
a hydrogen atom bonded to nitrogen, oxygen, or fluorine. Hydrogen bonding 
also plays an important role in controlling the ternary structures adopted by 
proteins and nucleic acid where hydrogen bonding between parts of the same 
macromolecule causes it to fold into a specific shape, which serves to 
determine the molecule’s physiological or biochemical functions. DNA-
inspired hydrogen-bond self-assembly has been used to create 
supramolecular cages, helical, linear, and macrocyclic structures. It has been 
reported that the synthesis of new DNA-based artificial nucleosides, and their 




can provide the basis to potentially expand the molecularity of DNA to a 
hexaplex (Rakotondradany et al., 2005). However, hydrogen-bonding-
associated self-assembly is usually difficult to quantify since it is based on the 
chemical ingredients and angle of the atoms involved. 
 
1.1.3.2 Applications of Self-assembled Polyelectrolyte Microfiber 
One of the cornerstones of this study is the formation of self-assembled 
microfiber driven by the interface self-assembly phenomenon of 
polyelectrolytes. In this study, we attempted to use both general mechanisms 
and specific effects. With regard to the general interfacial behavior, it is 
important to note the charge regulation of both polyelectrolyte complexes; the 
interplay between the two charge-modulating effects is the key to 
understanding the rationale of our observations. Oppositely charged 
polyelectrolytes could interact with each other to organize into multilayer 
architectures by sequential layering, which has been widely studied for 
application in drug delivery vectors and coatings. These arrangements can be 
formed at micro and nanoscale to assemble into ordered materials such as 
polyionic films and fibers. Polyelectrolyte multilayer assemblies have 
promising application potential as antireflection coatings, light-emitting diodes, 
and microcapsules. 
 
Interfacial fibers formed via interface assembly have also been explored, 
though not as extensively. Three types of biostructural units have been 
successfully assembled using the process of fiber formation by interfacial 




immobilized fiber, and cell-encapsulated fiber units (Wan et al., 2004b). 
Indeed, previous research on fiber formation between synthetic polymers 
(Morgan et al., 1959), and between chitosan and alginate fibers (Liao et al., 
2005) has confirmed the feasibility of such interfacial self-assembly systems. 
This approach offers the advantage of controlling the drug or gene 
concentration by varying the ratio of modified to non-modified polyelectrolyte 
used for fiber fabrication. Even fragile and highly resorbable fibers can be 
created, while their poor physical properties would preclude “post-fiber” 
modification. Fibers are produced in aqueous-based conditions that enable 
the inclusion of various biomolecules in the design. The usefulness of this 
approach has also been demonstrated by the flexibility of fiber formation. 
Polyelectrolyte fibers are fabricated at room temperature and do not require 
the denaturing of solvents needed for conventional fiber fabrication methods, 
making it simple to form scaffolds for tissue engineering and other medical 
applications. 
 
The fibers are fabricated by placing two droplets of oppositely charged 
solutions in close proximity and bringing them in contact using a needle or 
sharp tweezers. Fibers are formed from the interface of the two solutions until 
either one of the polyelectrolyte phases is exhausted. This process is 
compelled by the formation of a polyelectrolyte complexation as a result of 
electrostatic interplay at the interface. Various research groups have used this 
process to produce IPC fibers and have demonstrated the use of the fibers as 




proteins, drug molecules, DNA, and cells to provide local and sustained 
delivery of therapeutic agents. 
 
Wan and colleagues have hypothesized the mechanism for the formation of 
polyelectrolyte fibers (Wan et al., 2004a). According to their theory, a four-
step process leads to fiber formation by IPC. 
 
1) Formation of a polyionic complex film 
The two components in IPC are dissolved in water solutions. Fibers are drawn 
from the interface of the two aqueous solutions. Free mixing of oppositely 
charged polyelectrolytes must be avoided to maintain an interfacial 
phenomenon. A polyelectrolyte complex film forms at the interface, which 
functions as a viscous barrier to limit exchange of the polyelectrolytes. 
 
2) Nucleation 
Upon drawing up, the interface falls apart into many individual, complexed 
fields acting as nucleation sites for added fiber formation. The continuous 
upward movement of fiber causes these complexation points to promote 
further nucleation. 
 
3) Growth of nuclear fibers 
The viscosity of the free extra component outside the fibers decreases as a 
result of the increased size of nuclear fibers, due to the continuous drawing up. 
Therefore, the upward drawing motion contributes to the consecutive 





4) Coalescence of nuclear fibers 
Finally, the fibers produced from nucleation coalesce and the leftover 
polyelectrolytes consolidate into gel droplets along the fiber axis. The 
characteristic morphology of the fibers resulting from this coalescence 
produces a primary fiber comprising a number of secondary nuclear fibers 
wrapped together and scattered with gel-like beads. 
 
The fiber formed through the IPC process can be used to encapsulate 
materials at surrounding temperatures and under aqueous conditions, an 
attribute that is especially useful for the encapsulation of biologics such as 
DNA and viruses. The mode of IPC fiber formation by progressing thin fiber 
nucleation empowers the fiber to go “around” the particles’ fiber, which 
enlarges both the cross section and the mechanical strength of the fiber 
encapsulations. IPC fiber has been proposed as a building block and 
biological construct unit to create scaffolds or structures via a bottom-up 
approach for tissue engineering applications due to its novel feature of 
incorporating proteins, drug molecules, DNA nanoparticles, viruses, and cells. 
The assembly of biostructural units into the fiber constructs has been 
achieved by using human mesenchymal stem cell-encapsulated fiber units 
(Wan et al., 2004b). Cells in the resulting assembly could be successfully 
stimulated to differentiate along chondrogenic and osteogenic lineages, 
suggesting the active biological functions of such fibers. The encapsulating 
capability of this type of fiber has drawn increasing attention and this 




of the uniqueness of the fiber formation phenomenon, but also for its potential 
application for therapeutic tissue engineering. 
 
1.2 Objectives of This Study 
In this study, we intended to develop strategies to fabricate novel bio-
nanoparticles by conjugating functional polymer-coated magnetic 
nanoparticles with plasmid DNA and coupling the binary complex with 
biological active peptide through simple but stable electrostatic interactions 
with the purpose of enhancing the transfection efficiency. In terms of BV 
vectors, we established bio-nanoparticles by coating BV particles with 
magnetic nanoparticles that can be used to facilitate magnetically guided 
transduction to the surface of the cells. Moreover, we intended to engineer a 
process to assemble innovative bio-microfibers through the self-assembling 
behavior of macromolecules, including amphipathic and functional peptides 
with plasmid DNA and BV in order to protect BV vector from being inactivated 
by serum complement proteins. 
 
Non-viral magnetofection facilitates gene transfer by using a magnetic field to 
concentrate magnetic nanoparticle-associated plasmid delivery vectors onto 
target cells. In light of the well-established effects of the transactivating 
transcriptional activator (Tat) peptide, a cationic cell-penetrating peptide, in 
enhancing the cytoplasmic delivery of a variety of cargos, we proposed to test 
whether the combined use of magnetofection and Tat-mediated intracellular 
delivery improves transfection efficiency. We expected the plasmid DNA-




in vivo under the control of polymer-coated magnetic nanoparticles with the 
assistance of a functional peptide. We planned to apply the same approach to 
BV vectors to investigate the synergistic effect of magnetofection and Tat 
peptide on viral vector-mediated gene transfer. 
 
On another note, this study also addressed the subject of gene delivery 
through a structural route. We attempted to explore the self-assembling 
phenomenon of three biological molecules: plasmid DNA, BV, and a set of 
short peptides. Polyelectrolyte fibers composed of these molecules have been 
characterized extensively. There is evidence that virus particles are uniformly 
incorporated in the fiber structure itself upon successful encapsulation. These 
fibers, rich in amphipathic peptide residues, cover virus particles and mediate 
a sustained release when they dissolve in cell culture conditions, inducing 
transgene expression comparable with that of naked BV. Our primary goal 
was to ensure that BV retained almost complete transductional activity after 
encapsulation. Preliminary evidence also suggests that fiber encapsulation 
may prevent straightforward exposure of the virus to serum complement and 
thus protect it from inactivation by the complement components, which is a 
main barrier blocking the effective in vivo application of BV-mediated gene 
delivery. This evidence illustrates the advantage of using fiber encapsulation 
to deliver BV to mammalian cells both in vitro and in vivo. 
 
BV-based bio-nanoparticle and bio-microfiber vectors are expected to show 
better resistance to complement inactivation and therefore their potential 




modular approaches could also offer new possibilities for further advancement 
of plasmid and BV-based vectors, in terms of improved gene expression 
efficiency, passive tumor targeting, augmentation of biosafety profiles, 
prolonged gene expression duration, immune response shielding, and the 
introduction of new cellular targeting moieties, all of which are essential to 
strengthen BV particles and improve their performance at the transductional 
level. Modified BV complex vectors should replicate the advantages and 
circumvent the disadvantages of both non-viral and viral gene delivery 
systems, thereby offering improved gene delivery. In addition, the magnetic 
nanoparticle has led to the introduction of therapeutic BV, not just into the 
patient’s body, but to reach specific target sites. 
 
In this study, we concentrated on investigating the gene delivery performance 
in tumors originated from CNS with a particular focus on glioma cells, with the 
objective of providing useful gene delivery vector systems for the potential 
treatment of glioma tumors in the CNS. Luciferase and EGFP reporter genes 
were used to evaluate transgene expression profiles in human-glioma-derived 
cell lines. In addition, different gene delivery systems were used to deliver 
therapeutic genes to specific target cells in experimental animal models. We 
hoped to temporally and spatially regulate their expression patterns given the 
proper regulatory elements, to test the potential application of these systems 
to treat neurological diseases in the CNS. 
 
Our objective with this research was to establish an innovative bioengineering 




DNA and BV vectors. We hoped the platform technology generated in the 
project will be valuable in establishing effective and safe gene therapy vectors. 
Significant economic benefits may also emerge from the opportunity to 
develop advanced gene delivery vectors that can be potentially patented and 
commercialized. The project may further contribute to enhanced quality of life 
by improving the efficacy of gene therapy for CNS tumors. 
 
1.2.1 Specific Goals 
To establish appropriate delivery systems for gene therapy of neurological 
diseases in the CNS, vectors should be carefully selected and properly 
modified. One of the basic hypotheses underlying this study was that 
functional polymer-coated magnetic nanoparticles can interact with 
therapeutic plasmid DNA or BV vectors coupled with bio-active peptide to 
form bio-nanoparticle complexes, and the assembled bio-nanoparticles can 
potentially be applied for gene therapy of glioma tumors. Another fundamental 
assumption of this study was that polyelectrolyte fibers assembled through the 
interaction between positively charged amphipathic peptides and negatively 
charged plasmid DNA can be used to encapsulate BV to form bio-microfibers, 
and that the resulting complex vectors can achieve sustained release of BV, 
retaining transduction efficiency while offering improved therapeutic efficacy in 
the presence of serum complement proteins. 
 
These hypotheses were based on the following observations. First, the insect 
BV AcMNPV is a promising and established viral gene delivery vector (Boyce 




as reference in the study. Second, when employed in systemic administration, 
these viruses are easily inactivated after exposure to serum complements 
(Hofmann et al., 1998; Hofmann et al., 1999). Thus, our bio-nanoparticle and 
bio-microfiber design might protect the viruses against serum inactivation. 
Third, cationic polymers such as PEI can condense DNA into nanoparticles by 
electrostatic interaction, make it susceptible to degradation, and enhance 
cellular uptake via endocytosis. Although in vitro transduction with cationic 
polymers is efficient, in vivo results have not been encouraging, probably due 
to the large size formation of DNA condensed with cationic polymers, which is 
inefficient for cellular uptake by most cell solid tissues (Davis, 2002). Fourth, 
magnetic nanoparticle-aided gene delivery shows promise, based on the 
physical principle of magnetic separation and the ability to pull the employed 
gene expression vector toward the target cells or tissues, thereby 
accomplishing enhanced transfection level (Xenariou et al., 2006). Fifth, it has 
been well-established that the Tat peptide can be used to greatly enhance the 
cytoplasmic delivery of a variety of cargos, which could be used to improve 
the transduction efficiency of non-viral gene delivery vectors. Sixth, 
amphiphilic peptides have been established as versatile building blocks for 
self-assembled arrangements, while interfacial interactions of polyelectrolyte 
solutions, such as peptides, and polyelectrolyte fibers are an effective 





The main investigations of this study can be categorized into three parts: 
 
1. Studying the Possibility of Coupling Magnetic Nanoparticle-
conjugated DNA with Tat Peptide for Improved Gene Cellular Delivery 
Peptides derived from the Arginine-rich basic domain of the HIV Tat have 
recently been introduced to massively increase the efficiency of gene cellular 
delivery. However, no study to date has valued the potential application of this 
approach on DNA-shuffled gene transfer. In this study, cationic polymer (PEI 
25 kDa)-coated superparamagnetic nanoparticles were used as carriers for 
DNA, which can magnetically guide transduction in vitro and in vivo for the 
purpose of further increasing cell uptake of the gene transfer vector, and thus 
the transduction efficiency. 
 
A. Synthesis and Characterization of Tat Peptide-coupled Bio-
nanoparticles 
This study introduced both histidine and cysteine residues to the Tat 
peptide to facilitate the escape of gene vectors from endosome, with the 
objective of achieving higher efficiency of the magnetically guided 
transduction. We associated the modified Tat peptide to the DNA and 
magnetic particle complex and examined the enhancing effect of Tat on 





B. Gene Transfer Performance of Tat-associated Magnetic 
Nanoparticle Complexes 
The gene transfer performance of the bio-nanoparticle complex was 
assessed in terms of transduction efficiency to appraise the influence of 
Tat on the DNA, both in vitro and in vivo. We also investigated the 
magnetically guided transduction achieved by the magnetic particles upon 
application of an external magnetic field. 
 
2. Exploring the Protective Effects of Functional Polymer PEI-coated 
Magnetic Nanoparticles Against Viral Inactivation Triggered by Serum 
Complement by Forming Bio-nanoparticles  
Complement inactivation is a major obstacle affecting the gene transfer 
efficiency of BV in vitro in serum-containing medium conditions, and in vivo 
during systemic administration. 
 
A. Fabrication of Bio-nanoparticles 
In these studies, we presented a new method to generate bio-
nanoparticles with PEI-coated magnetic nanoparticles comprising BV 
vectors carrying a reporter gene. Through simple and stable electrostatic 
interactions, we incorporated PEI or magnetic nanoparticles to the surface 
of a BV vector on the basis that BVs are negatively charged on the surface 






B. Characterization of Assembled Bio-nanoparticles 
Surface charge and particle size measurements were carried out to 
characterize the charge and dimensional properties of the bio-
nanoparticles to evaluate the strength and mechanism of interaction 
between BV and PEI or magnetic nanoparticles, respectively. The 
knowledge obtained from this study should establish the basis for 
subsequent optimization and assembly conditions. 
 
C. Assessment of In Vitro and In Vivo Gene Delivery Performance 
This study focused on the effects on gene transfer efficiency, mainly 
reporter gene expression levels, in cultured glioma cells and other tumor 
cell lines in the presence of serum, shortly after viral transduction. Similarly, 
in animals this could be assessed after intracranial and intravenous 
injection to characterize the transductional activities of PEI or magnetic 
nanoparticle-modified BV vectors. 
 
D. Investigation of Magnetically Guided Transduction 
These studies evaluated the effect of magnetic force on the transduction 
efficiency of bio-nanoparticles upon the application of an external magnetic 
field. 
 
3. Investigating the Potential of Using Fiber to Protect BV against 
Serum Complement Inactivation 
To address the obstacles associated with BV-mediated gene delivery from a 




formed that incorporated the merits of existing non-viral and viral vectors while 
abolishing the deficiencies of both vector types. The underlying theme of this 
study is the interaction between positively charged polyelectrolyte, composed 
of functional peptides, and negatively charged polyelectrolyte solution, 
including plasmid DNA and BV. We attempted to use the polyelectrolyte 
complexation through interfacial phenomenon to create microfibers 
comprising peptides, DNA, and BV. 
 
A. Assembly of Bio-microfibers 
In this study, we tried to optimize the protocols and conditions for fiber 
formation between DNA and a set of peptides. Two types of peptides were 
used: Tat and Tat-derived peptides, and amphipathic peptides and a 
functionalized amphipathic peptide. Later, BV solution was combined with 
plasmid DNA solution to constitute the negatively charged polyelectrolyte 
for fiber formation. 
 
B. Characterization of Bio-microfibers 
Surface charge measurements were performed to characterize the charge 
properties of the bio-microfiber to evaluate the mode of interaction among 
peptide, plasmid DNA, and BV as well as the mechanism of the protective 
effect on BV against serum inactivation. Fluorescence labeling, confocal 
imaging, scanning electron microscopy (SEM), and light microscope 






C. Appraisal of Gene Delivery Performance 
BV-encapsulating fibers were used to perform transduction experiments in 
glioma cell lines in the presence of human serum complement to evaluate 
the transductional capability and protective ability of the bio-microfiber. 
Experimental animal models, where gene delivery vectors were exposed 
to high-concentration serum complement, were employed to investigate 
the therapeutic effect of the hybrid gene transfer vector. 
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2.1 Introduction 
2.1.1 Magnetofection: Magnetically Guided Nucleic Acid Delivery 
Magnetofection is a gene delivery method that uses an externally applied 
magnetic field to direct the accumulation of magnetic nanoparticle-modified 
gene transfer vectors in targeted cells and regions (Scherer et al., 2002; 
Dobson, 2006; Plank et al., 2003; McBain et al., 2008; Mykhaylyk et al., 2007). 
For example, PolyMag, a commercially available magnetofection vector, is 
produced by the conjugation of magnetic iron oxide nanobeads with positively 
charged, 25 kDa branched PEI. The PEI polymers are capable of binding to 
negatively charged plasmid DNA, enabling the whole complex to respond to 
an applied magnetic force. Magnetofection speeds up the sedimentation of 
gene transfer vectors to the cell surface and often shortens the time span of 
gene delivery to minutes of incubation, as opposed to the hours required for 
standard in vitro gene transfer procedures. Magnetofection also allows for the 
use of lower doses of vectors to deliver transgenic expression at a functional 
level, thus minimizing the toxic risk caused by high concentrations of gene 
delivery vectors. In addition to improving gene delivery into cultured cells, this 
method can be used to control in vivo gene delivery in the body to achieve 
magnetic field guided organ targeting. However, magnetofection facilitates 
only the diffusion process of vectors. Once the vector reaches the cell, 
overcoming membrane barriers—including the plasma membrane, endosomal 
membrane, and nuclear envelope—may still pose a challenge. For non-viral 
magnetofection to deliver plasmid nanoparticles, active functions that can 
overcome these membrane barriers are particularly important to promote 
plasmid entry into the cell nucleus for gene expression. 
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2.1.2 Tat Peptide-based Gene Delivery 
Tat is a highly cationic peptide derived from HIV-1 Tat protein, with a linear 
sequence of 13 amino acids (Brooks et al., 2005; Berry, 2008). This specific 
sequence carries a transmembrane and a nuclear localization signal. The 
membrane absorption is primarily promoted by ionic interaction between the 
cationic charge of the Tat peptide and anionic charge of the phospholipid 
heads in biomembranes. Benefiting from its cell membrane-penetrating 
properties, the Tat peptide is capable of mediating intracellular delivery of 
many different types of cargos (Brooks et al., 2005; Berry, 2008), including 
magnetic nanoparticles (Lewin et al., 2000). 
 
We developed an endosomolytic Tat peptide-based gene delivery vector by 
fusing the peptide with histidine residues (Lo and Wang, 2008). The imidazole 
group of histidine has a pKa of ~6.0 and can thus absorb protons in the acidic 
environment of the endosomes (pH 5–6.5), leading to osmotic swelling, 
membrane disruption, and eventually DNA escape. We also included two 
cysteine residues that contain the thiol group at both ends of the peptide. The 
cysteine amino acids can then interact with the cysteine residues of other 
peptides to form interpeptide disulfide bonds that stabilize peptide–DNA 
complexes. As covalent disulfide bonds are broken down, mainly under 
reducing conditions, plasmid DNA held within the complexes will not be 
released until it is introduced into the reducing environment of the endosomes, 
thus effectively protecting the DNA in the extracellular environment. 
Polymerization of the peptide through interpeptide disulfide bond formation 
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In this study, we hypothesized that the combination of magnetic field 
enhanced cell surface accumulation of magnetofection vectors and Tat 
peptide-mediated effective transmembrane function would provide an 
opportunity for high-efficiency gene transfer. To test this hypothesis, we 
generated ternary complex of PolyMag, plasmid DNA, and the endosomolytic 
Tat peptide through electrostatic interaction and examined its gene 
transfection efficiency in cultured human and mouse cells and in the spinal 
cord of rats. We also explored the protective effects of PolyMag on BV against 
the viral inactivation triggered by serum complement by forming bio-
nanoparticles, given that complement inactivation is a major obstacle affecting 
the gene transfer efficiency of BVs in vitro under serum-containing medium 
conditions, and in vivo during systemic administration. 
 
2.2 Materials and Methods 
2.2.1 Preparation of Magnetofection Complexes and Other Gene 
Transfer Vectors 
Magnetic nanoparticles coated with PEI 25 kDa (PolyMag) were purchased 
from Chemicell (Postfach, Germany). Bis(cysteinyl) histidine-rich, 
endosomolytic Tat peptides (Lo and Wang, 2008) were prepared using a 
conventional solid-phase, chemical synthetic method (GL Biochem, Shanghai, 
China) with a purity greater than 98%. The study used a plasmid DNA 
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encoding a firefly luciferase (Luc) gene under the control of the CAG promoter 
(pCAG-Luc, kindly provided by Yoshiharu Matsuura, National Institute of 
Infectious Diseases, Tokyo, Japan) and a plasmid DNA with a gene encoding 
an EGFP under the control of the CMV promoter (pFastBac-CMV.EGFP) 
(Zeng J et al., 2007a). To prepare magnetofection complexes, plasmid DNA 
and PolyMag were diluted in separate solutions of Milli-Q water mixed at a 
weight/weight ratio of 1 and incubated for 15 minutes at room temperature. 
The endosomolytic Tat peptides were then added to the PolyMag/DNA 
complexes in an N/P ratio as stated in the text and immediately mixed by 
vortexing for 30 seconds. The ternary mixtures were incubated for 30 minutes 
at room temperature. Oxidization of the endosomolytic Tat peptides was 
performed by air-bubbling of pure oxygen gas flow for 30 seconds, followed 
by shaking for 30 minutes in an Eppendorf Thermomixer®. This procedure 
was performed twice to ensure covalent bonds were formed between peptides. 
 
Other gene delivery systems tested in this study included two non-viral gene 
delivery systems: PEI/DNA complexes and Lipofectamine 2000/DNA 
complexes; and two viral vectors: recombinant BV and AAV type 2 (AAV-2) 
vectors. To prepare non-viral DNA complexes, plasmid DNA pCAG-Luc was 
mixed with PEI 25 kDa (Sigma-Aldrich, San Diego, CA, USA) at an N/P ratio 
of 15, or Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a ratio of 
plasmid DNA (in µg) to Lipofectamine 2000 (in µL) of 1:3. Recombinant BV 
vectors (Wang et al., 2006b) were constructed using the transfer plasmid 
pFastBac1 of the Bac-to-Bac® BV expression system (Gibco BRL, Life 
Technologies, USA) with a luciferase cDNA under the control of the human 
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CMV enhancer/promoter. Recombinant AAV-2 vectors (Wang et al., 2005a) 
were constructed by cotransfection of HEK293 cells using pAAV-CMV E/P-
Luc containing a luciferase reporter gene under the control of the human CMV 
enhancer/promoter, the AAV-2 packaging plasmid pAAV-RC, and the 
adenovirus helper plasmid pHelper purchased from Stratagene (La Jolla, CA, 
USA). 
 
2.2.2 Preparation of Baculovirus-based Bio-nanoparticles 
BV vectors that can express luciferase under the control of a CMV promoter, 
namely BV-CMV-Luc, were constructed using the Invitrogen Bac-to-Bac® 
system. To summarize, the expression cassette CMV-Luc was inserted into 
the pFastBacTM1 vector, which was used to transform DH10αBac competent 
cells, followed by the isolation of Bacmid plasmids containing the virus 
genome and expression. Sequentially, Bacmid was used to transfect host 
Spodoptera frugiperda (Sf9) insect cells to produce recombinant BVs. Budded 
viruses were then harvested and further amplified in the Sf9 cells. Virus 
stocks were stored at 4℃until use. Virus infectious titers were determined  by 
plaque assays with Sf9 cells. In this study, cationic polymer (PEI 25 kDa)-
coated superparamagnetic nanoparticles (PolyMag) were used to interact with 
BV particles. PolyMag nanoparticles were dissolved in water. BV particles and 
PolyMag were first adjusted to desired concentrations and then incubated 
separately for 5 minutes at room temperature to reach equilibrium, at which 
point they were shaken on the vertex machine for 1 minute to detach the 
particles remaining on the bottom and sides of the containers. Then the 
PolyMag solution and BV solution were mixed according to the desired 
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PolyMag concentration for interaction, shaken on the vertex machine for 
1 minute to ensure uniform dispersion of the particles, and then incubated at 
room temperature for 40 minutes to allow the formation of PolyMag-BV bio-
nanoparticles. 
 
2.2.3 Serum Complement Inactivation of Bio-nanoparticle Vectors 
After the formation of complex vectors, fetal bovine serum (FBS, Hyclone) and 
rat serum complements (Sigma) were applied to the particles for inactivation 
treatment. Serum complements were incubated with bio-nanoparticle 
solutions at a volume ratio of 1:1 at 37°C for 30 minutes. Heat inactivated 
(56°C for 30 minutes) serum complement from the same serum was used for 
the control. 
 
2.2.4 Characterization of Gene Transfer Vectors 
Particle sizes were determined by dynamic light scattering and zeta potentials 
were measured electrophoretically using Zetasizer Nano-ZS (Malvern 
Instruments, Malvern, UK). For TEM imaging, samples were prepared by 
dipping carbon-coated copper grids into sample solutions followed by drying 
at room temperature. TEM images of gene transfer particles were taken on a 
JEOL 100CX instrument operated at 200 kV. 
 
2.2.5 In Vitro Magnetofection 
Human U87, H4, and T98G glioma cell lines and human NT2 (Ntera-2/D1) 
neural stem cells were purchased from American Type Culture Collection 
(Manassas, VA, USA) and the U251 astrocytoma cell line was purchased from 
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the Chinese Academy of Science (Shanghai, China). The cell lines were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% FBS and 1% penicillin-streptomycin. Mouse C17.2 cells were kindly 
provided by Professor E. Arenas, Department of Medical Biochemistry and 
Biophysics, Karolinska Institute, Stockholm, Sweden, and were maintained in 
DMEM supplemented with 10% FBS (Gibco) and 5% horse serum (Gibco). 
 
For magnetofection, cells were seeded in 96-well plates at a density of 20,000 
cells per well in 50 µL of growth medium. Immediately prior to magnetofection, 
100 µL of fresh growth medium was used to replace the old medium. The 
complexes with 1 µg of plasmid DNA were then added to each well. 
MagnetoFACTOR plate (Chemicell), a permanent magnet, was placed under 
the cell culture plate and created a permanent magnetic field at the cell layer 
location with a field strength and gradient of 70 to 250 mT and 50 to 130 T m-1, 
respectively. After 15 minutes of incubation, the MagnetoFACTOR plate was 
removed to avoid cytotoxicity induced by overexposure to the magnetic field 
(Mykhaylyk et al., 2007). The medium with magnetofection complexes was 
then replaced with 100 µL of normal growth medium. The cells were cultivated 
under standard conditions for 24 hours before gene expression analysis. 
 
For luciferase gene expression analysis, the cells were rinsed with Phosphate 
Buffered Saline (PBS) and lysed with 50 µL of lysis buffer (Promega, WI, 
USA). A single freeze-thaw was performed to ensure complete lysis. Ten µL of 
the cell lysate was used for measurement with Luciferase Assay System 
(Promega). Measurements were made in a single-tube luminometer (Berthold 
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Lumat LB 9507, Bad Wildbad, Germany) for 10 seconds. The amount of 
protein in the lysate was measured by DC Protein Assay with bovine serum 
albumin as the standard. Results were expressed in relative light units (RLU) 
per mg total protein. 
 
For EGFP gene expression analysis, EGFP-positive cells in the 96-well plate 
were imaged by fluorescent microscopy 24 hours after magnetofection. The 
number of transfected cells was counted in an inverted fluorescent 
microscope using a 10 × objective with the view field accounting for one-
fiftieth of the well area. The EGFP-positive and total cells were counted in five 
view fields per well. Magnetofection efficiency was estimated by the average 
percentage of the fluorescent cells in triplicate. 
 
2.2.6 In Vivo Gene Transfer 
Adult male Wistar rats (200–250 g) were used for in vivo gene transfer. In 
animals anesthetized by an intraperitoneal injection of sodium pentobarbital, 
the lumbar injection was given using a 10-μL micro-syringe connected with a 
30-gauge needle after exposing the skin around L4-L5. Slight movement of 
the tail reflected proper injection into the subarachnoid space. Twenty µL of 
magnetic complexes with 4 µg of pCAG-Luc was injected slowly into each rat 
over 5 minutes. The doses for other gene transfer vectors were 4 µg of 
plasmid DNA in non-viral PEI 25 kDa/DNA or Lipofectamine 2000/DNA 
complexes, 1 x 108 particles of AAV-2, and 1 x 107 particles of BV, each in 20 
µL doses. After injection, the needle remained in situ for 5 minutes before 
being slowly withdrawn. The skin was then closed with surgical clips. An 
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externally applied magnetic field (NdFeB permanent magnet, 1.21 Tesla, 
New-Era Electro-Magnetic Int’l, Singapore) was used immediately after 
injection by placing the magnet on top of the injection site for 15 minutes. 
Alternatively, the injected magnetic complexes were moved up the spinal cord 
by shifting the magnet repeatedly from the injection site to the brain for 
15 minutes. 
 
For luciferase activity assays of tissue samples, animals were perfused 
transcardially with 0.1 M PBS 2 days after injection and the spinal cord was 
collected. The spinal cord was separated into cervical, thoracic, and lumbar 
parts. The tissue samples were homogenized with 400 µL of lysis buffer 
(Promega), followed by three freeze-thaw cycles. The lysate was centrifuged 
at 14,000 g for 5 minutes at 4°C, and supernatants were collected for 
luciferase activity assay as described above. For immunostaining, animals 
were perfused transcardially with PBS, followed by 
4% paraformaldehyde/0.05% glutaraldehyde in PBS. The lumbar spinal cord 
was removed and sections were cut at 30 µm thickness. The sections were 
transferred to gelatin-coated slides and fixed with acetone. A goat anti-
luciferase (1/200, Dako, Carpinteria, CA, USA) and a fluorescein 
isothiocyanate-conjugated anti-goat polyclonal antibody were used as the 
primary and secondary antibodies, respectively. After antibody incubation and 
washing, the sections were mounted in FluorSave™ (Calbiochem, San Diego, 
CA, USA) and photographed. 
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2.2.7 Statistical Analysis 
All data are represented as the mean ± SD. The statistical significance of 
differences was determined by the two-factor analysis of variance (ANOVA) 
with replication followed by Tukey post hoc analysis or unpaired Student’s t-
test. A P value of <0.05 was considered statistically significant. 
 
2.3 Results 
2.3.1 Formation of Ternary Magnetofection Complexes 
The amino acid sequence, chemical structure, and 3D structure modeling of 
our endosomolytic Tat peptides are shown in Figure 2.1A. The bulky imidazole 
groups of histidine residues are oriented on both sides of the peptide 
backbone in a spiral pattern to minimize steric hindrance. The rigid backbone 
of the peptide suggests that an interpeptide disulfide bond will form only 
between two cysteine residues from two peptides. To form stable and active 
complexes, the reversible polymeric forms of the Tat peptide with terminal 
cysteine residues were prepared by oxidative polymerization via the terminal 
thiol groups by simple infusion of pure oxygen gas into the mixtures. After 
1 hour of incubation under oxidative conditions, the zeta potential and size of 
the complexes were measured. As shown in Figure 2.1B, PolyMag iron 
particles had a particle size of approximately 10 nm as determined by 
dynamic light scattering analysis. When PolyMag and plasmid DNA 
complexes were prepared at a magnetic nanoparticle iron-to-DNA ratio of 1:1 
(wt/wt), the size of the binary complexes was approximately 120 nm. The zeta 
potential of PolyMag iron particles was 50 mV, while the zeta potential of the 
PolyMag/DNA complexes decreased to 30 mV, suggesting that some of the 
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negatively charged plasmids were exposed on the surface of the complexes. 
Including the endosomolytic Tat peptides into the complexes, at an N/P ratio 
between peptide and plasmid DNA of 3:1, reversed the zeta potential from 
30 mV for the PolyMag/DNA binary complexes to approximately 50 mV for 
PolyMag/DNA/Tat ternary complexes, whereas the complex size remained 
approximately 120 nm. These results demonstrate the surface coating of 
positively charged Tat peptides. Further increasing the Tat peptide from an 
N/P ratio of 3:24 did not result in any obvious change in zeta potential and 
complex size (Figure 2.1B). 
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Figure 2.1 - Endosomolytic Tat peptide and ternary magnetofection complexes. 
(a) The amino acid sequence, chemical structure, and 3D modeling of the 
endosomolytic Tat peptide. The 3D modeling was based on “3D structure 
optimization” in ACD/ChemSketch freeware v10. The 3D structure was rotated to 
achieve a viewing angle from one end of the peptide. (b) Particle size and zeta 
potential measurements of various types of complexes (n = 3). To prepare binary 
complexes, PolyMag and plasmid DNA were mixed at a ratio of 1 (wt/wt). To prepare 
ternary complexes, various amounts of the Tat peptide were incubated with the 
binary complexes at an N/P ratio between peptide and plasmid DNA as indicated 
previously. Tat, transactivating transcriptional activator. 
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2.3.2 Electron Microscopic Analysis of Bio-nanoparticles 
TEM images of PolyMag, PolyMag/DNA binary complexes, and 
PolyMag/DNA/Tat peptide ternary complexes are shown in Figure 2.2. The 
PolyMag nanoparticles (Figure 2.2A) displayed a smooth, spherical 
morphology with an average particle diameter of 10 nm, a size consistent with 
that obtained by dynamic light scattering analysis (Figure 2.1B). After mixing 
PolyMag with plasmid DNA, the particles tended to aggregate together 
(Figure 2.2B). The TEM image showed two phases: crystalline and 
amorphous, corresponding to PolyMag and plasmid DNA, respectively, 
suggesting electrostatic interaction between cationic PEI polymer-coated 
PolyMag and negatively charged plasmid DNA. After adding Tat peptides to 
the PolyMag/DNA binary complexes, the amorphous phase outside PolyMag 
nanoparticles, as well as the crystal lattice of PolyMag, was still clearly 
observed (Figure 2.2C). These TEM findings demonstrate the successful 
formation of PolyMag/DNA and PolyMag/DNA/Tat complexes. The 
corresponding schematic illustration of the structure of PolyMag/DNA/Tat 
peptide ternary complexes is shown in Figure 2.2D. 
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Figure 2.2 - Electron microscopic analysis of PolyMag nanoparticles, binary, 
and ternary magnetofection complexes. PolyMag nanoparticles are shown in (a). 
PolyMag/DNA binary complexes (b) were prepared at a weight ratio of 1 and 
PolyMag/DNA/Tat peptide ternary complexes (c) at a weight ratio of 1 plus an N/P 
ratio of 12. Note the outside amorphous phase wrapping layer and the inside 
crystalline phase of PolyMag nanoparticles in binary and ternary magnetofection 
complexes. (d) The schematic illustration of the structure of PolyMag/DNA/Tat 
peptide ternary complexes. Tat, transactivating transcriptional activator. 
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2.3.3  In Vitro Transfection Efficiency of Bio-nanoparticles 
To optimize conditions for magnetofection complex preparation to achieve 
effective transfection, we first determined the optimal ratio of PolyMag to 
plasmid DNA for transfection in human astrocytoma cell line U251. Cells were 
transfected with these complexes when a magnet was placed under the cell 
culture plate. After 15 minutes of transfection, the magnet was removed and 
the transfection medium was replaced with a fresh normal medium. At 
magnetic nanoparticle iron-to-DNA ratios ranging from 0.5 to 2 (wt/wt), 
maximal transgene expression was achieved at the ratio of 1 (Figure 2.3A). 
While the addition of various amounts of the Tat peptide during complex 
preparation did not obviously change the zeta potential and size of 
PolyMag/DNA/Tat complexes (Figure 2.1B), we did observe an alteration of 
luciferase transgene expression when using different complexes prepared 
from an N/P ratio between peptide and plasmid DNA of 3:24 (Figure 2.3B). 
When the Tat peptide was used at an N/P ratio of 3, we observed no 
improvement in gene expression compared to the gene expression level 
provided by PolyMag/DNA binary complexes. The Tat peptide improved gene 
expression after the N/P ratio was increased to 6 and provided the highest 
expression level, with up to four-fold improvement over the complexes without 
the Tat peptide, at an N/P ratio of 12. Further increasing the N/P ratio resulted 
in a decline in the level of transgene expression. This decrease after the 
addition of more Tat peptides implies a negative impact from the formation of 
too many interpeptide disulfide bonds, which might affect intracellular plasmid 
DNA release from the complexes. In a control experiment, we performed 
transfection of U251 cells with these PolyMag/DNA/Tat ternary complexes in 
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the same manner as above, but without the use of a magnet plate. We 
observed very low levels of gene transfer in the absence of a magnetic field, 
regardless of which N/P ratio was used to add Tat peptides (Figure 2.3B). This 
finding indicates that the addition of the endosomolytic Tat peptide alone, 
without the influence of a magnetic field, will not significantly improve 
transfection efficiency under these transfection conditions, and that the 
complex-bound Tat peptides play an enhancement role only after a magnetic 
field has pulled the complexes to the surface of the cells. 
 
In addition to the U251 cells tested above, we also used other types of neural 
cell lines, including human glioblastoma U87 cells, mouse C17.2 neural stem 
cells, and human NT2 neural stem cells. Although the absolute values of 
transfection efficiency under a magnetic field varied in these cells, 
PolyMag/DNA/Tat ternary complexes prepared at an N/P ratio of 12 provided 
significantly higher levels of luciferase gene expression than PolyMag/DNA 
binary complexes without the Tat peptide (Figure 2.3D). A similar improvement 
in gene expression was observed when the EGFP reporter gene was tested in 
U251 cells (Figure 2.4). In this case, the transfected cells were imaged by 
fluorescent microscope and the efficiency of gene delivery was determined by 
counting the number of EGFP-positive cells (Figure 2.4A). The maximum 
number of EGFP-expressing cells was obtained at an N/P ratio of 12, with 
approximately 60% positive cells (Figure 2.4B). When the complexes 
prepared at N/P ratios higher than 12 were used for transfection, the efficiency 
of transfection was reduced significantly to a level even lower than that 
obtained by using PolyMag/DNA binary complexes without the Tat peptide, 
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suggesting again the negative effect of a high number of disulfide bonds, 
possibly on intracellular plasmid DNA release. 
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Figure 2.3 - Endosomolytic Tat peptides increase magnetofection-mediated 
luciferase reporter gene expression in vitro. (a) Effects of weight ratios between 
PolyMag and plasmid DNA on transgene expression. Binary complexes were 
prepared at ratios (wt/wt) from 0.5 to 2. Human U251 astrocytoma cells were 
transfected. (b) Effects of the Tat peptide. The binary complexes prepared in (a) at a 
weight ratio of 1 were mixed with endosomolytic Tat peptides to generate ternary 
complexes. The Tat peptides were added at different N/P ratios between peptide and 
plasmid DNA, as indicated previously. Human U251 astrocytoma cells were 
transfected. (c) Comparison of binary and ternary magnetofection complexes in 
different cell lines. Binary complexes were prepared at a weight ratio of 1 and ternary 
complexes at a weight ratio of 1 plus an N/P ratio of 12. Human glioblastoma U87 
cells, mouse C17.2 neural stem cells, and human NT2 neural stem cells were used. 
The results are presented as mean RLU of luciferase activities per mg of cellular 
protein and standard deviations are indicated with error bars (n = 5). * P<0.05 versus 
the wt/wt ratio of 0.5 by ANOVA in (a), * P<0.05, ** P<0.01, *** P<0.001 versus the 
N/P ratio of 0 by ANOVA in (b), and ** P<0.01, *** P<0.001 versus the PolyMag/DNA 
group by Student’s t-test in (c). RLU, relative light unit; Tat, transactivating 
transcriptional activator. 
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Figure 2.4 - Endosomolytic Tat peptides increase magnetofection-mediated 
EGFP reporter gene expression. Human U251 astrocytoma cells were transfected 
with binary or ternary magnetofection complexes. Binary complexes were prepared 
at a weight ratio of 1 and ternary complexes at a weight ratio of 1 plus different N/P 
ratios between peptide and plasmid DNA, as indicated previously. (a) Fluorescence 
microscopic images of EGFP expression. (b) Histograms summarizing the 
quantification of the percentage of transfected EGFP-positive cells. The mean values 
of triplicate experiments are presented and standard deviations are indicated by error 
bars. ***, significantly higher than the group with N/P ratio of 0, P<0.001 by ANOVA 
and +++, significantly lower than the group with N/P ratio of 0, P<0.001 by ANOVA. 
EGFP, enhanced green fluorescent protein; Tat, transactivating transcriptional 
activator. 
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2.3.4 In Vivo Gene Delivery Efficiency of Bio-nanoparticles 
In conjunction with our research interest in gene delivery into the CNS, we 
further compared the in vivo gene transfection efficiencies of PolyMag/DNA 
binary complexes and PolyMag/DNA/Tat ternary complexes after 
administering the complexes into the spinal cord through lumbar intrathecal 
injection. A magnetic field was applied by placing a magnet on the back of the 
animals to prevent gene transfer complexes from being carried away by 
cerebrospinal fluid (CSF) flow. The level of transgene expression provided by 
ternary complexes was approximately two times higher than that provided by 
the binary complexes (Figure 2.5A). This expression level of the ternary 
magnetofection complexes was also higher than that provided by two 
commonly used non-viral gene delivery systems: PEI 25 kDa/DNA complexes 
and Lipofectamine/DNA complexes (Figure 2.5B). Although we made no 
attempt to control parameters that might affect quantitative comparison of the 
efficiencies between magnetofection and viral systems, it appeared that the 
ternary complexes mediated a level of transgene expression higher than that 
provided by AAV-2, but lower than that provided by BVs (Figure 2.5B). The 
improved magnetofection by the Tat peptide was confirmed by 
immunostaining of the cryostat sections of the lumbar spinal cord using 
luciferase antibodies (Figure 2.5C). Stronger staining, mainly in spinal 
meninges, was observed after injection of the ternary complexes. Several 
positively stained cells were observed in spinal parenchyma only when the 
ternary complexes were used. 
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We next tested whether it is possible to achieve magnetic field-guided region 
targeting in the spinal cord. After the intrathecal injection of the ternary 
magnetofection complexes, a group of animals were exposed to an external 
moving magnetic field. Instead of remaining immobile as in the previous in 
vivo experiment, the magnet placed on the back of this group of animals was 
repeatedly moved slowly along the spinal cord from the lumbar injection site 
to the brain. Under this moving magnetic field, the overall transfection 
efficiency in the spinal cord was improved by more than two-fold over that 
under a motionless magnetic field (Figure 2.6A). Of particular note, moving 
the magnet along the spinal cord effectively changed the regional pattern of 
transgene expression (Figure 2.6B). Using a motionless external magnetic 
field, luciferase transgene expression was detected mainly in the thoracic and 
lumbar regions that were close to the lumbar injection site. With the moving 
magnetic field, the peak-level expression was detected in the cervical spinal 
cord remote from the injection site, with the lowest level of transgene 
expression in the lumbar spinal cord. These findings demonstrate that 
magnetic guidance can be used to retarget intrathecally injected gene transfer 
vectors in the spinal cord. 
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Figure 2.5 - Binary or ternary magnetofection complexes and in vivo luciferase 
reporter gene expression in the rat spinal cord. Binary complexes were prepared 
at a weight ratio of 1 and ternary complexes at a weight ratio of 1 plus an N/P ratio of 
12. Magnetofection complexes were injected intrathecally into the lumbar spinal cord 
in rats, followed by placement of a magnet on the animals’ backs for 15 minutes. The 
spinal cord was collected 2 days later for analysis. (a) Endosomolytic Tat peptides 
increase transgene gene expression as determined by luciferase activity assay. The 
mean values of five rats are presented and standard deviations are indicated by error 
bars. * P<0.05, *** P<0.001 versus the PolyMag/DNA group by Student’s t-test. 
(b) Luciferase gene expression from four vectors 2 days after lumbar intrathecal 
injection. Results are presented as RLU per tissue and standard deviations are 
indicated by error bars. (c) Endosomolytic Tat peptides increase transgene gene 
expression as determined by immunostaining of cryostat sections of the lumbar 
spinal cord using luciferase antibodies. A strong staining in the meninges of the 
spinal cord was observed after injection of ternary magnetofection complexes. The 
original photographs were taken at x 200 magnification. RLU, relative light unit; Tat, 
transactivating transcriptional activator. 
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Figure 2.6 - Effects of a moving magnetic field on the distribution of transgene 
expression in the spinal cord. (a) Luciferase activities in the lumbar, thoracic, and 
cervical segments of the spinal cord under the influence of a motionless or moving 
magnet field. (b) Percentage of luciferase expression levels in each segment. The 
mean values of five rats are presented and standard deviations are indicated by error 
bars. * P<0.05 versus the group under the influence of a motionless magnet field by 
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2.3.5 In Vitro Transduction Efficiency of Baculovirus-based Bio-
nanoparticles 
We further examined whether PEI 25 kDa-coated magnetic nanoparticles 
(PolyMag) can interact with BV and thus magnetically assist the viral-
mediated gene transfer process. We performed the in vitro study on the U251 
cell line to test this theory. As indicated in Figure 2.7, in the absence of serum, 
the luciferase expression level of BV vectors decreased significantly upon the 
application of 4 μL PolyMag per 100 μL BV solution in comparison with the 
group of untreated BV, revealing that strong interactions exist between 
negatively charged BV and positively charged magnetic nanoparticles. In 
contrast, the inhibitory effect of PolyMag on BV was reversed in the presence 
of serum as the transduction efficiency was dramatically increased with the 
elevation of the PolyMag concentration, which implies the significant in vivo 
application potential of PolyMag-BV bio-nanoparticles. Moreover, the 
transductional activity of PolyMag-BV vectors was approximately 16-fold 
higher than that achieved by naked BV when magnetic force was applied, an 
indicator that gene delivery performance in a serum-containing environment 
could be greatly improved by forming bio-nanoparticles with PolyMag. We 
noticed the trend of transduction efficiency by BV with varied concentrations 
of PolyMag was in opposite directions, in the absence and presence of serum. 
A possible explaination is that BV envalop proteins could be coated by 
PolyMag particles therefore preventing their interation with cell recepters. 
However, this shielding effect coincidentally provided protection against 
serum complement inactivation in the serum containing medium during the 
transduction process. Meanwhile, magnetic force played an important role in 
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enhancing the luciferase expression of the PolyMag-BV complex, as indicated 
by comparing the results obtained with and without a magnetic plate during 
transduction in the serum-containing medium. These results suggest the 
multifunctionality of PolyMag-BV bio-nanoparticles to simultaneously achieve 
magnetically guided transduction and protection of BV against serum 
complement inactivation. 
 
To confirm the strength of PolyMag-BV bio-nanoparticles in terms of 
enhancing transduction efficiency with the existence of serum, we carried out 
similar transduction studies on several different cell lines, including HepG2, 
Hela, and NIH-3T3. As shown in Figures 2.8 to 2.10, the transduction 
efficiency profiles of all three cells are consistent with that of U251, although 
the extent to which transduction efficiency was increased varied among 
different cell types. These efficiency differences could arise because of the 
different mechanisms by which bio-nanoparticles enter cell membranes and 
are transported into the nucleolus, as well as the variant tolerances of 
different cell lines to the cytotoxicity of bio-nanoparticle vectors. We also 
carried out transduction experiments in the presence of rat serum, with the 
results (Figure 2.11) indicating that PolyMag-BV bio-nanoparticles work as 
well in rat serum as in FBS. 
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Figure 2.7 - Transduction capabilities of PolyMag-BV bio-nanoparticles in U251 
cells without (a) or with (b) serum complement inactivation. PolyMag-BV 
complexes were used to transduce U251 cells without or with pre-treatments of 
serum complement inactivation. FBS was used for inactivation treatments. MOI  50 
was used for transduction. Luciferase expression was quantified as RLU per mg 
protein. BV, baculovirus; FBS, fetal bovine serum; MF, magnetic force; MOI, 
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Figure 2.8 - Transduction capabilities of PolyMag-BV bio-nanoparticles in 
HepG2 cells without (a) or with (b) serum complement inactivation. PolyMag-BV 
complexes were used to transduce HepG2 cells without or with pre-treatments of 
serum complement inactivation. FBS was used for inactivation treatments. MOI 50 
was used for transduction. Luciferase expression was quantified as RLU per mg 
protein. BV, baculovirus; FBS, fetal bovine serum; MF, magnetic force; MOI, 
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Figure 2.9 - Transduction capabilities of PolyMag-BV bio-nanoparticles in Hela 
cells without (a) or with (b) serum complement inactivation. PolyMag-BV 
complexes were used to transduce Hela cells without or with pre-treatments of serum 
complement inactivation. FBS was used for inactivation treatments. MOI 50 was 
used for transduction. Luciferase expression was quantified as RLU per mg protein. 
BV, baculovirus; FBS, fetal bovine serum; MF, magnetic force; MOI, multiplicity of 
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Figure 2.10 - Transduction capabilities of PolyMag-BV bio-nanoparticles in NIH-
3T3 cells without (a) or with (b) serum complement inactivation. PolyMag-BV 
complexes were used to transduce NIH-3T3 cells without or with pre-treatments of 
serum complement inactivation. FBS was used for inactivation treatments. MOI 50 
was used for transduction. Luciferase expression was quantified as RLU per mg 
protein. BV, baculovirus; FBS, fetal bovine serum; MF, magnetic force; MOI, 
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Figure 2.11 - Transduction capabilities of PolyMag-BV bio-nanoparticles in rat 
serum without or with serum complement inactivation. PolyMag-BV complexes 
were used to transduce U251 cells without or with pre-treatments of serum 
complement inactivation. Rat serum complement was used for inactivation 
treatments. MOI 50 was used for transduction. Luciferase expression was quantified 
as RLU per mg protein. BV, baculovirus; MF, magnetic force; MOI, multiplicity of 
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2.3.6 Zeta Potential of Baculovirus-based Bio-nanoparticles 
To explore the mechanism by which bio-nanoparticles protect BV against 
serum inactivation, we attempted to evaluate the charge properties of such 
complexes. Study results showed that the zeta potential of BV alone at 
physiological pH is -18 mV, while bio-nanoparticles have a zeta potential of 
approximately +25 mV at the same pH, suggesting that the negatively 
charged BV particles are probably coated or at least partially coated by the 
positively charged magnetic nanoparticles, thereby protecting BV from 
exposure to the serum environment (Figure 2.12). 
Production, Characterization and Evaluation of Bio-nanoparticles 





Figure 2.12 - Zeta potential measurements of various types of complexes. To 
prepare binary complexes, PolyMag and BV were mixed at a ratio of 4 μL/108 BV 
particles. Measurements were carried out from buffer pH 3 to pH 10 for BV particles 
(a) and PolyMag particles (b) alone, while for bio-nanoparticles (c) the pH 
movements of ascending and descending directions were applied. Results shown 
were averages of five independent measurements. BV, baculovirus. 
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2.4 Discussion 
Tat peptide delivery strategy is widely used to improve intracellular delivery of 
various types of molecular cargos. Tat peptide function lies on its transduction 
domain, a small, basic, amino acid-rich stretch (RKKRRQRRR) that conveys 
the cell membrane penetrating property (Brooks et al., 2005; Berry, 2008). 
Tat-mediated intracellular delivery is believed to occur directly through the 
plasma membrane following the inverted micelle formation. After membrane 
absorption, the peptide is scavenged into a hydrophilic pocket by 
phospholipids reorganization (Brooks et al., 2005; Berry, 2008). Using a 
transducible Tat-Cre recombinase reporter assay on live cells, it has also 
been shown that after an initial ionic cell-surface interaction, Tat-fusion 
proteins are rapidly internalized by lipid raft-dependent macropinocytosis, and 
a transducible, pH-sensitive, fusogenic dTat-HA2 peptide can markedly 
enhance Tat-Cre escape from macropinosomes (Wadia et al., 2004). The 
mechanisms by which the Tat peptide enables cargos to cross cell plasma 
membranes are effectively complementary to the functions of magnetofection, 
a process that improves cell surface accumulation of genetic materials. Thus, 
when the two approaches are used together, genetic materials effectively 
adhere to and then cross the cell membrane. Although it was previously 
reported that Tat peptide-derived magnetic nanoparticles can be efficiently 
internalized into stem cells for cell imaging (Lewin et al., 2000), the current 
study documents for the first time that the Tat peptide can significantly 
improve the efficiency of magnetofection-based gene transfer. This new non-
viral gene transfer method combines the unique features of the two well-
established delivery approaches, i.e., magnetic nanoparticles-based plasmid 
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transfer and Tat peptide-based intracellular delivery, and is able to mediate 
gene transfer both in vitro and in vivo. 
 
We previously developed a method to prepare ternary complexes of low 
molecular weight PEI, plasmid DNA, and a peptide derived from the nerve 
growth factor for targeted neuronal gene delivery (Zeng et al., 2007b), which 
demonstrated that it is crucial to apply cationic polymers first to condense 
plasmid DNA to an extent that some of the negatively charged DNA 
molecules are still exposed on the surface for peptide binding. After using 
PolyMag and the Tat peptide to replace low molecular weight PEI and the 
neuron targeting peptide, we applied the principle of our previous study to 
generate self-assembled complexes in the current study. To prepare ternary 
magnetofection complexes, we first mixed PolyMag, a PEI 25 kDa-coated 
magnetic iron bead, with plasmid DNA. An appropriate amount of PolyMag 
was required to form complexes that provide efficient transfection. Small 
quantities of PolyMag beads at a wt/wt ratio of 0.5 were not sufficient for DNA 
binding, while large quantities of PolyMag beads might affect cell survival due 
to the cytotoxicity of PEI 25 kDa (Mykhaylyk et al., 2007), resulting in a 
decrease of transfection efficiency. As suggested by the decreased zeta 
potential and increased particle size, binary complexes formed at the wt/wt 
ratio of 1 contain some negatively charged plasmid DNA molecules exposed 
on the surface. Positively charged endosomolytic Tat peptides were then 
introduced into the binary complexes through electrostatic interaction. The 
significant increase of zeta potential after incubation of the binary complexes 
with the Tat peptides suggests that the peptides had been absorbed on the 
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surface of the ternary complexes. No obvious change in complex size is an 
indication that adding the Tat peptides to the complexes did not cause further 
DNA condensation, probably due to the relatively small molecular weight of 
the peptide. Oxidation-induced polymerization of the peptide through 
interpeptide disulfide bond formation on the surface may prevent dissociation 
of the small Tat peptides from the complexes. Thus, the exposure level of the 
Tat peptide was assumed to be higher, consequently facilitating its membrane 
translocation action. This may have promoted the cellular uptake of the 
magnetofection complexes after a magnetic force pulled them to the cell 
membrane. Within the cell, both the endosomolytic Tat peptide and PEI 
25 kDa can promote endosomal escape of the complexes through proton 
absorption in the endosomes. The nuclear localization signal of the Tat 
peptide may further promote plasmid DNA entry into the cell nucleus for 
transgene expression. In the context of the synergistic effect between PEI 
25 kDa and the Tat peptide, our results are consistent with previous 
publications, which demonstrated that cell-penetrating peptide-modified PEI 
25 kDa displayed enhanced transfection efficiency in vivo in the mouse lung 
(Kleemann et al., 2005; Nguyen et al., 2008). 
 
One of the interesting findings of our study is that magnetic guidance can be 
used to overcome the distribution limit of intrathecally injected gene transfer 
vectors. Intrathecal injection in the lumbar spinal cord is a low-invasive 
procedure and poses little danger of injuring nerve roots, as CSF in the 
relatively wide subarachnoid space allows a certain degree of mobility of the 
nerve roots in response to needle puncture. Lumbar puncture may circumvent 
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the blood–brain barrier for drug delivery into the CNS and has been used as 
an access method for spinal anesthesia and for the introduction of therapeutic 
or diagnosis agents. The distribution of drugs delivered in this way is limited 
due to CSF flow, however. In our previous studies (Zeng et al., 2007b; Shi et 
al., 2003; Wang et al., 2005b), PEI/DNA complexes delivered through lumbar 
intrathecal injection resulted in gene expression mainly in the lumbar and 
thoracic spinal cord. This distribution was not improved even when using 
polyethylene glycol-grafted PEI/DNA complexes (Shi et al., 2003). In the 
current study, gene expression was redirected to the cervical spinal cord by 
application of a moving magnetic field. It appears that the magnetic 
complexes delivered through lumbar intrathecal injection responded to the 
externally applied magnetic field and moved within the CSF toward a location 
remote from the injection site. This is, to our knowledge, the first example of 
magnetic field guided targeting in the CNS. 
 
In addition, our preliminary discoveries with PolyMag-BV bio-nanoparticle 
mediated gene transfer in vitro open up the possibility of achieving improved 
gene delivery performance in vivo. Following complexation between BV and 
PolyMag, Tat peptide could be linked to the complex for interaction to facilitate 
the escape of gene vectors from endosome, thereby achieving higher 
efficiency of the magnetically guided transduction. The gene transfer 
performance of the bio-nanoparticle complex can be assessed in terms of 
transduction efficiency to appraise the influence of Tat on the BV, both in vitro 
and in vivo. PolyMag-BV complex without Tat modification can be employed 
as a control to determine whether Tat plays a role in increasing cell uptake of 
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the vectors being used. More importantly, this system can be applied to 
investigate the potential protective effect of bio-nanoparticles on BV against 
serum inactivation, which is a main obstacle blocking the in vivo application of 
BV-mediated gene therapy in preclinical studies. 
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3.1 Obstacles of Baculovirus-mediated Glioma Therapy 
Glioma is a type of primary CNS tumor originating from glial cells with the 
tendency to aggressively invade the surrounding brain tissue. Even when 
treated with complete surgical excision, radiation therapy, and chemotherapy, 
high-grade gliomas almost always grow back and patients usually die within a 
year, with only a few patients surviving longer than 3 years (Ohgaki and 
Kleihues, 2004; Ohgaki et al., 2005). Developing effective therapeutic 
strategies for gliomas is one of the current focuses in cancer therapy. Gene 
therapy, though still at the stage of preclinical and clinical trials, has shown 
promise in therapeutic intervention of gliomas. It has gained sufficient efficacy 
to serve as a viable stand-alone treatment or at least a supplement to the 
conventional glioblastoma treatments. To fulfill its potential, treatment methods 
require gene transfer vehicles capable of efficiently transducing tumor cells. 
As the majority of patients undergoing adenovirus-mediated gene therapy for 
glioma are likely to develop a pre-existing immune response to this commonly 
used gene transfer vector, insect BV-based vectors have recently been 
introduced as promising viral gene delivery vectors to overcome obstacles 
inherent in the animal viral systems that are commonly used at present. 
Researchers have established novel methods for glioma treatment through 
the use of recombinant BV vectors containing the diphtheria toxin A gene 
(Wang et al., 2006a). However, upon systemic administration, BVs often suffer 
the drawback of becoming inactivated following exposure to serum 
complement proteins. Since BV is of insect origin and was not subjected to 
human complement system during evolution, they likely did not evolve a 
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defensive mechanism to tolerate the attack from the human complement 
system (Hofmann and Strauss, 1998). 
 
3.1.2 Current Approaches to Complement Inactivation 
Previous reports showed that by using the surface display method, which 
fuses functional elements into the virus envelope proteins, it is possible to 
realize improved resistance of BV to serum complement inactivation (Hüser et 
al., 2001). One example is the successful incorporation of decay-accelerating 
factor into the BV envelope, with the result of a BV resistant to serum 
complement (Guibinga and Friedmann, 2005). By analogy with recombinant 
retroviral vectors, BVs modified with vesicular stomatitis virus G (VSV-G) 
protein also displayed complement resistance. A VSV-G–modified BV 
effectively transduced hepatocytes after injection into the tail veins of mice 
(Barsoum et al., 1997). Several research groups have also demonstrated that 
co-administration of complement inhibitors is an effective way of eliminating 
serum susceptibility (Hofmann et al., 1999; Hoare et al., 2005). Moreover, 
recombinant BVs displaying a polypeptide sequence of a heterologous virus 
were produced by a research group in Taiwan, and the authors maintain that 
the hybrid virus-like particles were resistant to serum complement inactivation 
(Ho et al., 2004). These results suggest the possible use of recombinant BV 
vectors in combination with surface modification techniques for in vivo gene 
therapy. Although modification of the viral surface has improved the efficiency 
of gene transduction into various cultured cell lines, in vivo gene delivery 
efficiency of recombinant BVs is still unsatisfactory. Meanwhile, tremendously 
time consuming and difficult molecular cloning work is usually required for 
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such biological modifications. It is also difficult or even impossible to precisely 
control the extent of modifications, even though processes such as surface 
display and pseudotyping can change the surface composition of the 
recombinant BV. Moreover, these biological modifications are inflexible in that 
they can only be performed during the vector construction process, after 
which further modifications are extremely hard to carry out. Thus, more 
flexible and simple modalities that facilitate the construction of the viral vector 
surface by altering the composition, modifying the structure, conjugating 
functional components, etc., are urgently needed to broaden the application of 
BV vectors in brain tumor-targeted CNS gene delivery, especially when 
angiogenesis occurs and results in the presence of blood and serum proteins 
in tumor tissues. 
 
Compared with biological modification methods such as surface display 
technique, the complexation approach opens up more versatile and superior 
possibilities of protecting BV against serum complement inactivation. It has 
been shown that the virus particle pegylation can be used to overcome the 
obstruction of complement inactivation and improve the in vivo gene delivery 
performance of BV vectors (Kim et al., 2006). Also, Yang and colleagues have 
demonstrated that through simple but stable electrostatic interactions, PEI, a 
well-established gene delivery vector, can be incorporated to the surface of 
the BV vector. The resulting PEI-BV complex vectors showed enhanced 
resistance to complement inactivation, greatly amplifying their potential 
application for in vivo gene delivery (Yang et al., 2009). Experimental data 
from our group’s studies have verified the use of PEI-coated magnetic 
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nanoparticles to improve the transduction efficiency of BV in the presence of 
serum complement under the control of an external magnetic force. 
Meanwhile, ongoing research efforts in our group have also shown that 
surface conjugation of BV particles with functional peptide can effectively fight 
against serum destruction. Altogether, these encouraging achievements have 
proven the validity of generating BV-based complex vectors to protect against 
complement inactivation, thus improving its in vivo gene delivery performance. 
 
3.1.3 Possibility of Protecting Baculovirus with Microfiber 
During the course of seeking appropriate complexation methodologies, the 
innovative principle of fiber formation by IPC attracted our attention. The IPC 
fiber has been proposed as a biostructural unit for biological assembly with its 
ability to incorporate proteins, drug molecules, DNA nanoparticles, and cells 
for tissue engineering applications. A polyelectrolyte fiber can be fabricated by 
drawing together two droplets of high concentration solutions of oppositely 
charged polyelectrolytes (Wan et al., 2004a). The unique feature of the IPC 
fiber formation process lies in its ability to encapsulate materials at room 
temperature and in aqueous solutions. This flexibility has enabled its 
application in the encapsulation of biologics. The mechanism of IPC fiber 
formation is supposed to create thin nuclear fibers that merge, providing a 
means by which biomolecules can be encapsulated within the fiber without 
compromising their physical properties and biological functions, making the 
fiber bypass the incorporated particles. Three types of biostructural units have 
been constructed using the process of IPC fiber formation: protein-
encapsulated fiber, ligand-immobilized fiber, and cell-encapsulated fiber. 
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Biological substances can be released from the fiber in a controlled manner 
and still exert normal bioactivity (Wan et al., 2004b; Liao et al., 2005). 
Depending on the component properties, the release time of encapsulated 
components from these fibers can be manipulated to cater to various 
requirements. As a result, this promising technique can be potentially 
functionalized by producing drug-loaded fibers with high encapsulation 
efficiency, sustained release kinetics, and the ability to maintain the bioactivity 
of the encapsulants (Liao et al., 2005). 
 
3.1.4 Objectives 
Motivated by achievements in IPC fiber formation and equipped with the 
knowledge offered by previous studies, we hypothesized that polyelectrolyte 
fiber formed by IPC could be used to encapsulate BV particles to protect them 
against serum complement inactivation. In this study, we evaluated the 
protectivity of IPC fiber on BV to assess its potential for in vivo applications in 
glioma gene therapy. The foundation of this hypothesis is the electrostatic 
interaction between positively charged polyelectrolyte composed of functional 
peptides, and negatively charged polyelectrolyte solution including plasmid 
DNA and BV. This proposal was clarified by initially investigating the effect of 
various parameters on the formation of fibers comprising a combination of 
plasmid and BV particles as the polyanion, and amphiphilic or Tat peptide as 
the polycation, and then examining the transduction efficiency and therapeutic 
efficacy of the fiber complex. 
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To test this hypothesis, we established procedures to evaluate the protective 
effect on BV of fibers formed through self-assembly of polyelectrolytes 
comprising plasmid DNA and a set of in-house designed amphiphilic peptides 
of alternating Leucine, Alanine, and Arginine residues or Tat peptide and its 
derivative. Afterward, we created a human brain tumor xenograft model in 
nude mice to assess the therapeutic effect of fiber-encapsulated BV vectors 
on glioma tumors. Fibers of polyelectrolyte complexes were synthesized by 
combining the peptides and plasmid DNA using the IPC process. 
Recombinant viruses encapsulated in such fiber not only transferred reporter 
genes into human glioma cell lines in vitro, but also effectively suppressed the 
tumor growth in nude mice in vivo. The finding of synergistic interactions of 
viral and non-viral vectors can assist in developing multimodal cancer gene 
therapies. Hopefully, the outcomes produced by this study will enrich the 
development of gene therapies of CNS disorders, especially glioma tumors, 
and will enable the advancement of BV, material engineering, and gene 
delivery-related studies. 
 
3.2 Materials and Methods 
3.2.1 Materials Used for Fiber Formation 
Plasmid DNA 
Plasmid DNA was employed as a vector backbone encoding the firefly 
luciferase gene (pCAG-Luc, kindly provided by Yoshiharu Matsuura, National 
Institute of Infectious Diseases, Tokyo, Japan). The plasmid was dissolved in 
Milli-Q water (Millipore, Massachusetts, USA) to required concentrations and 
stored at -20°C. Another plasmid DNA used to form fiber was pFastBac1 
Encapsulation of Baculovirus with Polyelectrolyte Fiber to Form Bio-microfiber 
                                                                                                                      
 79 
(Invitrogen), followed by the insertion of the expression cassette of CMV-
EGFP or CMV-Luc. 
 
Peptides 
All of the peptides were chemically synthesized and purified by GL Biochem 
(Shanghai, China). They were provided in powder form and resuspended in 
Milli-Q water at the required concentrations and stored at -20°C. A list of 
peptides used in the study is as follows: 
Name Sequence No. of Amino 
Acids 
Tat GRKKRRQRRRPPQC 14 
C-H5-Tat-H5-C CHHHHHGRKKRRQRRRPPQCHHHHHC 26 
AR10 ARARARARAR 10 
AR20 ARARARARARARARARARAR 20 
LR10 LRLRLRLRLR 10 
LR16 LRLRLRLRLRLRLRLR 16 
LR10RGD LRLRLRLRLRGRGDS 16 
 
Baculovirus vectors 
CMV-Luc BV with a luciferase reporter gene under the control of a CMV 
promoter, and CMV-EGFP BV under the control of a CMV promoter, were 
constructed using the Bac-to-Bac® BV expression system (Invitrogen, 
Carlsband, CA, USA). In summary, the expression cassette of CMV-Luc or 
CMV-EGFP was inserted into the pFastBac1 vector, which was then used to 
transform DH10Bac competent cells. After transformation, Bacmid plasmids 
containing the virus genome and expression cassettes were extracted and 
Encapsulation of Baculovirus with Polyelectrolyte Fiber to Form Bio-microfiber 
                                                                                                                      
 80 
used for the subsequent transfection of host Sf9 insect cells. Sf9 insect cells 
pre-adapted to Sf-900 II serum-free medium were purchased from Invitrogen, 
grown in spinner flasks at 27.5°C, and used to produce and propagate 
recombinant BV vectors. Budded viruses in the insect cell culture medium 
were collected and filtered through a 0.45-size filter (Millipore, Bedford, MA, 
USA) to remove any contamination, and concentrated by high-speed 
centrifugation at 28,000 g for 60 minutes. Viral pellets were resuspended in 
appropriate volumes of 0.1 M PBS and stored at 4°C. Virus infectious titers 
(plaque-forming units, PFU) were determined by plaque assays on Sf9 cells. 
 
BV vectors harboring the HSV thymidine kinase (HSV-TK) suicide gene, 
under the control of a human high-mobility group box 2 (HMGB2) promoter, 
were constructed as previously described (Balani et al., 2009). In summary, 
we first replaced the luciferase gene in the pGL4.11 vectors accommodating 
the 0.5-kb HMGB2 promoter with an HSV-TK gene obtained from pORF-TK 
(Invivogen) using PCR (forward primer, 5′ -ATGCCTCGAGTCTT
TCCTACAGCTGAGATCAC-3′ and reverse primer, 5′-ATGCTCTAGAAATGTA
TCTTATCATGTCGAGCTAGC-3′). The promoter and the HSV-TK gene were 
then subcloned into the pFastBac Dual vector (Invitrogen) between BamH1 
and Xba1. A fragment with the HSV-TK gene alone, without the promoter, was 
subcloned into the Not1 and Xba1 sites of the pFastBac, using Dual vector to 
produce a promoterless vector as the negative control. The Bac-to-Bac® BV 
expression system (Invitrogen) was then used to generate Bacmid DNA and 
subsequent BV, as previously described. 
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3.2.2 Fiber Formation Procedures 
Aqueous solutions of peptides and plasmid DNA were prepared at 8 mg/mL 
concentration. To draw one fiber, 5 μL droplets each of the positive electrolyte 
and negative electrolyte were deposited on a plastic Petri dish in close 
proximity with each other; spacing between the droplets was kept at less than 
50 μm. The interface of the droplets was then pulled together using a pair of 
tweezers, and the fiber was drawn in a continuous upward movement from 
the interface. There was some amount of residual solution left after each 
drawing due to disruption of the stable interface. Fibers can be drawn using 
10 μL and even 20 μL droplets of polyelectrolytes, but the volume of residual 
solution increases when using larger volumes. Using 5 μL droplets for each 
fiber ensures minimum wastage of materials. For BV encapsulation, the 
concentrated virus a titer of 109 PFU per mL was mixed with plasmid DNA of 
concentration 8 μg/μL in a volume ratio of 1:3 followed by vortexing for 5 
minutes. The resulting solution constituted the negative electrolyte for fiber 
drawing. Fibers were drawn against different peptide solutions at a 
concentration of 8 μg/μL. 
 
3.2.3 Scanning Electron Microscope 
DNA-peptide fibers with or without BV encapsulation were deposited onto the 
surface of a freshly prepared wafer holder wrapped with aluminum foil and air 
dried at room temperature for 4 hours. The wafer was then mounted onto an 
Al sample holder and sputter-coated with gold. The fiber morphology was 
examined using SEM (XL 30 FEG Philips, Hillsboro, OR, USA) at a 
magnification of 6671 x with an electron energy of 5 keV. 
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3.2.4 Field Emission Scanning Electron Microscope 
Fiber morphology was determined using a JEOL JSM-5600 SEM. The fibers 
were gold-coated for imaging with a JEOL JFC-1200 fine coater using a 
coating current of 20 mA and sputter time of 120 seconds. The samples were 
imaged under high vacuum at an accelerating voltage of 10 kV. 
 
3.2.5 Nuclear Magnetic Resonance 
All samples were prepared by dissolving approximately 10 mg of materials in 
1 mL of deuterium oxide (D2O). NMR was performed with a Bruker DPX300 
NMR Spectrometer at 300 MHz Ultrashield Plus and analyzed with in-house 
software at room temperature. The spectral width was 4789 Hz with 16 k data 
points. Chemical shifts were analyzed by referencing to the solvent peak 
(delta = 4.8 ppm for D2O). 
 
3.2.6 Viscosity Measurements 
Viscosity measurements of the samples were performed with a HAAKE 
Rheoscope 1 rheometer (Karlsruhe, Germany) using a cone and plate 
geometry of 6 cm diameter, 0.903°C cone angle, and a measurement gap of 
0.024 mm. The measurements were performed at room temperature at a 
constant shear rate of 10 per second for 5 minutes. 
 
3.2.6 Fluorescence Labeling of Biomolecules 
Stock solution of Bisbenzimide (Hoechst 33258) fluorescent dye (Sigma 
Chemical Company, Missouri, USA) was prepared by dissolving the dye in 
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Milli-Q water (Millipore, Massachusetts, USA) at a concentration of 1 mg/mL 
and storing in the dark at 4°C. The labeling solution was prepared by diluting 
the stock solution with water to a final concentration of 5 μg/mL. The labeling 
solution was mixed by vortexing with 8 μg/μL plasmid DNA using a volume 
ratio of 1:1. For PI labeling, Propidium Iodide (Sigma Aldrich, USA) was 
prepared at a concentration of 1 mg/mL. The labeling solution was prepared 
by diluting the stock to a final concentration of 20 μg/mL. The 10 μL of DNA 
was mixed with the dye and allowed to react for 2 hours in the dark. The LR10 
peptide was labeled with fluorescein isothiocyanate (FITC). The 1M stock 
solution was diluted to 0.01 M for labeling purposes. The reaction was done at 
a dye to peptide molar ratio of 1:1. BV particles were labeled with a Cy5 
mono-reactive dye pack (Amersham Biosciences, UK). The virus was 
resuspended in sodium carbonate–sodium bicarbonate buffer, mixed, and 
incubated with dye for 30 minutes. The labeled virus was centrifuged at 
28,000g for 60 minutes followed by thorough washing with 0.1M PBS. The 
centrifugation and washing was repeated to ensure complete removal of 
unreacted dye. The virus particles were resuspended in 0.1M PBS and used 
for fiber formation. 
 
3.2.8 Confocal Microscopy 
The labeled fiber was visualized under a confocal microscope (Olympus, 
Fluoview 300, Tokyo, Japan) using a 10x objective lens. The FITC excitation 
and emission was 510 nm and 530 nm, respectively. The PI excitation and 
emission was 490 and 635 nm, respectively. The confocal imaging for EGFP 
expression in U251 cells was completed using an LSM 510 microscope (Carl 
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Zeiss, Germany). The fibers were drawn and placed on a glass coverslip 
inserted in 24-well plates. The cells were allowed to incubate on top of the 
fibers at 37°C for 48 hours to allow for EGFP expression. After 48 hours, the 
cell culture medium was removed and the cells were washed with 0.1M PBS. 
The cells were fixed using 3.7% buffered paraformaldehyde for 15 minutes at 
37°C. The coverslips were then extracted from the well-plate and visualized 
under a confocal microscope. 
 
3.2.9 Surface Charge Measurements 
An electrokinetic analyzer (AntonPaar GmbH, Austria) was used to measure 
the surface zeta potential of the fibers. The fibers were prepared as previously 
described, air dried, and inserted in a stamp cell for measurement. The 
measurement was performed at pH 6.5 and 26°C. A dilute electrolyte (0.1 mM 
potassium chloride, pH 6.5) was circulated through the measuring cell 
containing the fiber sample, creating a pressure difference. The zeta potential 
value was calculated as the average of 5 measurements for each sample. The 
fiber was drawn using 5 μL droplets of both peptide solution and plasmid 
solution, with or without BV. The fiber containing BV was prepared with a BV 
and plasmid solution volume ratio of 1:3. 
 
3.2.10 In Vitro Transduction and Gene Expression Assessment 
For transduction assays, a human U87 glioblastoma cell line was grown in 
DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 g/mL 
streptomycin. The cells were maintained in a humidified incubator with 5% 
CO2 at 37°C. Cells at 50 to 70% confluency in 48-well plates were transduced 
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with CMV-Luc BVs or PEI-coated BVs for 1 hour, followed by removal of the 
BVs and addition of the DMEM supplemented with 10% FBS. Cells were 
washed 36 hours later with PBS and permeabilized with a reporter cell lysis 
buffer (Promega, WI, USA). Luciferase expression was measured by a single-
tube luminometer for 10 seconds (Berthold Lumat LB 9507, BadWildbad, 
Germany). 
 
3.2.11 Cell Transfection by DNA 
Human U87 glioblastoma cells were used for this portion of the study. For the 
lipofectin group, 10 μg of DNA was diluted in 100 μL of Opti-MEM® I Reduced 
Serum Medium and 10 μL of Lipofectin® was diluted in 100 μL of Opti-MEM® 
I Medium. After standing at room temperature for 40 minutes, the diluted DNA 
was combined with diluted Lipofectin® (total volume = 200 μL), mixed gently, 
and incubated for 15 minutes at room temperature. For the fiber groups, 10 μg 
of DNA was used to form fiber with peptide or peptide and BV using the same 
ratio as previously described. For the mixture groups, the same amounts of 
plasmid DNA were mixed together with the appropriate amount of peptide or 
peptide and BV used previously to form the fiber. U87 cells were transfected 
in 24-well plates per cell by pDNA, pDNA+AR20, pDNA+AR20+BV-EGFP, 
pDNA/AR20 fiber, pDNA/AR20/BV-EGFP fiber, and pDNA+Lipofectin. Cells 
were cultivated in the growth medium for 24 hours before completing the 
luciferase assay. The results are shown as mean RLU of luciferase activities 
per mg of cellular protein (mean ± SD, obtained from five replicate assays). 
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3.2.12 Cell Viability Assay 
Cell survival rates were measured by MTS assay (Promega) as per the 
manufacturer’s instructions. Cells were seeded onto 24-well plates at 1 × 105 
cells per well in DMEM supplemented with 10% FBS and transduced with 
various BV complexes at a designated MOI. The spectrophotometric assay for 
cell proliferation was performed 48 hours later by measuring OD at 490 nm. 
 
3.2.13 Flow Cytometry 
Fluorescence-activated cell sorting (FACS) analysis was used to quantify the 
transduction efficiency of BV vectors. After trypsinization to detach U87 cells 
from the culture plate, the cells were collected, washed in PBS, and 
resuspended in PBS before analysis with FACSCalibur Flow Cytometer (BD, 
Biosciences). 
 
3.2.14 Serum Complement Inactivation 
Human serum complement (Sigma-Aldrich) was reconstituted in 1 mL of 
sterile deionized water. For inactivation treatment, the human serum 
complement was incubated with the BVs, fiber-encapsulated BVs, or BV 
mixed together with plasmid DNA and peptide with designated volume at 37°C 
for 30 minutes. 
 
3.2.15 Animal Studies 
A nude mice tumor model was established by inoculating 1×106 U87 human 
glioblastoma cells expressing luciferase reporter genes subcutaneously on 
both thigh legs and tumors with the size of 2×107 so that a luciferase reading 
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could be observed after 7 days using the IVIS imaging system (Xenogen 
Corp., Alameda, CA). The injection procedure was performed under 
anesthesia by intraperitoneal injection of ketamine/xylazine (150/10 mg/kg). 
Intratumor injections were used for in vivo delivery. 100 μL of sample solution 
containing BV, BV in fiber, BV+pDNA+AR20, or PBS was injected into each 
animal on day 7 and day 14. The fiber was made as previously described. 
Fibers were cut into small segments and resuspended in PBS followed by 
vertex before injection. Each animal received 200 μL of ganciclovir (GCV) (5 
mg/mL) by intraperitoneal injection daily from day 8 to day 20. IVIS images 
were taken and luciferase readings of tumors were measured every 2 days; 
animal death was recorded accordingly. Briefly, bioluminescence was 
measured non-invasively using IVIS. Luminescent images were taken as a 
60-second acquisition 20 minutes after intraperitoneal injection of 200 μL of 
luciferin (5 mg/mL). During image acquisition, mice were anaesthetized 
continuously via inhalation of 3% isoflurane. Image analysis and 
bioluminescent quantification was performed using Living Image software 
(Xenogen Corp.). All remaining animals were sacrificed 60 days post-tumor 
implantation and the tumor size was recorded at that time. Tumor size was 
measured by a caliper and calculated as 0.5 x width2 x length and shown as 
cm3 at day 60. In the handling and care of animals, we followed the 
Guidelines on the Care and Use of Animals for Scientific Purposes issued by 
National Advisory Committee for Laboratory Animal Research, Singapore. 
The experimental protocols of the current study were approved by the 
Institutional Animal Care and Use Committee, National University of 
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Singapore and Biological Resource Center, and the Agency for Science, 
Technology and Research, Singapore. 
 
3.2.16 Statistical Analysis 
All data are represented as the mean ± SD. The statistical significance of 
differences was determined by the two-factor analysis of variance with 
replication followed by ANOVA analysis using SigmaStat 3.1 software. The 
statistical analysis of survival data was performed using the log rank test. A 
P<0.05 was considered statistically significant. 
 
3.3 Results 
3.3.1 Fiber Formation and Characterization 
Seven types of peptides were used to form interfacial fibers with plasmid DNA. 
These peptides can be divided into two groups: four amphiphilic peptides 
including in-house designed AR10, AR20, LR10, and LR16 with alternating 
hydrophobic and positively charged amino acids; and two HIV-coded Tat 
regulatory peptides. For the cell attachment study, we also tested the fiber-
forming ability of a hybrid peptide comprising LR10 and LR10 functionalized 
with an Arg-Gly-Asp (RGD) motif with a 1:1 molar ratio. Two droplets of 
oppositely charged electrolyte solutions were placed on the disc. The 
interface of the droplets was then pulled together using tweezers, and the 
fiber was drawn in a continuous upward movement from the interface 
(Figure 3.1A). First, we optimized the peptide and plasmid concentration 
required for fiber formation and found that the optimal concentration is 8 μg/μL 
for amphiphilic peptides and 9 μg/μL for Tat peptide and its derivative. The 
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optimal fiber-forming concentration of plasmid solution was 8 μg/μL for 
interaction with both types of peptides. Light microscopy, florescence 
microscopy, and confocal microscopy were used to investigate fiber 
morphology and prove the presence of components,. We demonstrated that 
all seven peptides were able to interact with plasmid DNA to form 
polyelectrolyte fiber through IPC with various morphologies (Figure 3.1B). The 
AR10 and AR20 peptides formed homogeneous straight fibers with clear 
edges, showing a relatively uniform dimension of ~10 μm in width and 2 to 
5 cm in length. The LR10, its derivative, and LR16 peptides, however, formed 
homogeneous straight fibers with varying dimensions of 5 to 50 μm in width 
and 5 to 20 cm in length, due to the fact that the width varies depending on 
the length of the fiber drawn. For Tat peptide and its derivative, homogeneous 
straight fibers can also be assembled with a dimension of ~20 μm in width 
and 5 to 10 cm in length. Florescence microscopy images of the LR10 fibers 
resembled those visualized by light microscopy. The plasmid DNA were 
labeled with Hoechst blue, a fluorescent dye that binds to the minor groove of 
the DNA, and the fibers assembled using such plasmids were viewed under 
fluorescent microscopes to validate the constitution of the fiber. The results 
suggest that DNA molecules were evenly incorporated in the fibers as one of 
its components (Figure 3.1C). We further performed confocal scans by 
labeling the peptide with FITC green dye and plasmid DNA with PI at a 1:1 
molar ratio to double confirm the constitution and explore the inner structure 
of the fiber. We found that both peptide and plasmid DNA were present in the 
fiber, as indicated by their respective colors, suggesting both ingredients are 
involved in the fiber formation process (Figure 3.1C). We also noticed several 
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consecutive yellow regions in the superimposed images (results not shown) 
where the DNA and peptide overlapped, indicating some binding and 
interaction between peptide and plasmid, although the scope and degree of 
such interactions were unclear. 
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Figure 3.1 - Formation and characterization of peptide–DNA fibers. (a) 
Schematic of the fiber drawing process. For drawing one fiber, 5 μL droplets of the 
positive electrolyte and negative electrolyte were deposited on a plastic Petri dish in 
close proximity with each other. The interface of the droplets was then pulled 
together using a pair of tweezers, and the fiber was drawn in a continuous upward 
movement from the interface. (b) Morphology of the fibers formed using seven types 
of peptides drawn against plasmid DNA. Concentrations of 8 μg/μL were used for 
each of the peptides and for the plasmid DNA. Fibers were drawn between plasmid 
DNA and each of these peptides. Fibers were air dried for 5 minutes to a semi-dry 
state and laid on a cell culture disc. PBS was poured into the disc to submerge the 
fiber surface to mimic the cell culture condition. The fibers were viewed under a 
transmission microscope at 10x magnification. (c) Fluorescence microscope images 
of a LR10-DNA fiber with Hoechst blue labeled DNA at 10x magnification. Images 
show uniform incorporation of DNA in the fibers. All images were taken with the fiber 
in a wet state for better visualization. (d) Confocal scans of fiber with fluorescent-
labeled peptide and DNA. The confocal microscopy images show LR10-DNA fiber 
made of FITC-labeled peptide and PI-labeled DNA using a 10x objective lens. The 
images show equal incorporation of the two biomolecules in the fiber. The excitation 
for FITC was 510 nm and emission was 530 nm. The excitation and emission for PI 
were 490 and 635 nm, respectively. FITC, fluorescein isothiocyanate; PBS, 
Phosphate Buffered Saline; PI, Propidium Iodide. 
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3.3.2 Encapsulation of Baculovirus with Fiber 
Having confirmed the fiber-forming ability of peptide and plasmid, we 
attempted to encapsulate BV with such fibers with the purpose of protecting it 
from serum complement inactivation. Previous results from our studies have 
suggested that BVs have a net negative surface charge of ~20 mV at 
physiological pH. Therefore, we presumed that fibrous structures could 
potentially be formed through electrostatic interaction between a positively 
charged peptide and a negatively charged complex constituted from plasmid 
and BV particles. By combining concentrated plasmid solution and BV PBS 
solution, we demonstrated that it is possible to draw fibers against various 
peptide solutions using the fiber-forming approach described above. The BV 
particles were suspended in 0.1M PBS at a titer of 1 x 109 PFU per mL, using 
the previously optimized plasmid concentration of 8 μg/μL. We found the ratio 
of 3:1 between plasmid and BV solutions produced the best quality fibers. The 
BV containing fibers had similar dimensions as fibers without virus 
encapsulation, when observed under light microscope (Figure 3.2A). Fiber 
morphology analysis, however, revealed that the dimensions of BV-containing 
fibrous structures varied dramatically depending on the length of the fiber 
drawn, namely the longer fiber we have drawn, the diameter of the fibers 
becomes thinner given total amount of polyelectrolyte solutions is fixed. Field 
emission SEM (FESEM) was used to study the surface morphology of the 
fibers formed through self-assembly of the AR20 peptides and plasmid DNA, 
with and without BV encapsulation (Figure 3.2B), as it is capable of creating 
clearer, less electrostatically distorted images withspatial resolution down to 
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1.5 nm, which is 3 to 6 times better than conventional SEM. FESEM 
photographs of both types of fiber revealed the formation of fibrous 
assemblies of microfibers with similar morphology and dimensions as 
observed under light microscope. It was evident, however, that the surface 
appearance of these two fibers differed greatly. The fiber without BV 
incorporation displayed a smoother surface with very few ridges along the 
fiber axis. The fiber with BV incorporation, however, showed a much rougher 
surface morphology with clear ridges along the fiber axis, probably due to the 
encapsulation of nano-sized BV particles or aggregates of BVs inside the 
nuclear sub-microfibers composing the microfiber as a whole. Conventional 
SEM photographs of microfibers formed through self-assembly of AR20 
peptide and plasmid DNA with BV incorporation (Figure 3.2B) once again 
showed the prominent indents and even clearly identified aggregates of BV 
particles. Fluorescence microscopy images of fiber consisting of BV labeled 
with Cy5 confirmed that the virus particles were successfully incorporated into 
the fiber (Figure 3.2B). We further characterized the charge property of the 
fiber by measuring the surface zeta potential of the AR20 and LR10 fiber. The 
results showed that peptide–DNA fiber has a general negative surface zeta 
potential at pH 7.4 and 25°C for both types of fiber, probably caused by the 
highly negatively charged DNA molecule. However, a significantly lower 
surface zeta potential was produced by introducing BV particles in the fiber-
forming process due to the negatively charged surface of the virus particles 
(Figure 3.2C). 
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Figure 3.2 - Characterization of peptide–DNA fibers encapsulating BV. 
(a) Morphology of the fibers formed using seven types of peptides drawn against a 
plasmid DNA and BV mixture. Concentrations of 8 μg/μL were used for each of the 
peptides and for the plasmid DNA. BV and plasmid solution were mixed together with 
a 1:3 volume ratio. The titer of the BV solution was 109 PFU. Fiber was drawn using 5 
μL droplets of both peptide solution and BV plus plasmid solution. Fibers were air-
dried for 5 minutes to a semi-dry state and laid on a cell culture disc. PBS was 
poured into the disc to submerge the fiber surface to mimic the cell culture condition. 
The fibers were viewed under a transmission microscope at 10x magnification. 
(b) (upper panel) FESEM images of fibers without and with BV. Fiber morphology 
was determined using FESEM. (b) (lower panel left) A SEM micrograph of peptide–
DNA fibers encapsulating BV, indicating floating BV on the fiber surface. (b) (lower 
panel right) Fluorescence microscopy of virus encapsulated in fibers. BV was labeled 
using Cy5. The virus was resuspended in sodium carbonate–sodium bicarbonate 
buffer, mixed, and incubated with dye for 30 minutes. The labeled virus was 
centrifuged at 28,000g for 60 minutes followed by thorough washing with 0.1M PBS. 
(c) The zeta potential of the peptide–DNA fiber without and with BV encapsulation. 
The measurement was performed at pH 6.5 and 26°C. A dilute electrolyte (0.1 mM 
KCl, pH 6.5) was circulated through the measuring cell containing the fiber sample, 
creating a pressure difference. The zeta potential value is the average of 5 
measurements for each sample. The fiber was drawn using 5 μL droplets of both 
peptide solution and plasmid solution, with or without BV. The fiber containing BV 
was prepared with a BV and plasmid solution ratio of 1:3. BV, baculovirus; FESEM, 
field emission scanning electron microscopy; KCI, potassium chloride; PBS, 
Phosphate Buffered Saline; PFU, plaque-forming units; SEM, scanning electron 
microscopy. 
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3.3.3 Transduction Ability of Bio-microfiber 
Having demonstrated the ability to encapsulate BV in the peptide–DNA fiber, 
we proceeded to test the in vitro transduction efficiency of BV released from 
fibers in U87 human glioma cell lines. Self-assembled polyelectrolyte fibers 
comprising AR20 peptide, DNA, and BV carrying an EGFP or luciferase 
reporter gene were produced and laid on the 24-well cell culture plate, 
followed by application of U87 cells suspended in media. Prior to the addition 
of cell suspensions, one group of the transduction reagents was treated with 
human serum complement, whereas the other control group was treated with 
PBS blank solution. Gene expression assessment was carried out 48 hours 
post-transduction. Results showed that a comparable number of cells can be 
transduced in the fiber group as compared with the naked BV group in the 
absence of human serum complement treatment. Though the intensity of 
fluorescence in the fiber group was slightly lower than the positive control, the 
number of green cells infected was at the same level (Figure 3.3A). On the 
other hand, the transduction efficiency of the fiber group was substantially 
higher than the naked BV group in the presence of human serum complement, 
suggesting that fiber encapsulation can effectively protect BV from inactivation 
by complement proteins (Figure 3.3A). Moreover, we found that in the 
presence of human serum complement treatment, the percentage of EGFP-
positive cells in the fiber group was significantly higher than that of the mixture 
group, where the AR20 peptide was mixed together with plasmid and BV 
solution under the same conditions without forming fibrous structures, 
indicating that the protective effect is only functional when ordered microfiber 
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arrangements are formed (Figure 3.3A). The transgene expression pattern, 
and therefore the protective capability of fiber in the experimental groups, was 
also corroborated and verified by the luciferase expression profiles of BVs 
carrying a luciferase reporter gene, with or without serum inactivation in U87 
cells (Figure 3.3B). We also demonstrated that of the seven types of peptide 
used for fiber formation, only AR20 is capable of effectively protecting BVs 
against serum complement inactivation (data not shown). 
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Figure 3.3 - Transduction efficiencies of peptide–DNA fiber with BV 
encapsulation and peptide, DNA, and BV mixture after human serum 
complement treatment. Human U87 glioblastoma cells were used. Cells were 
transduced at an MOI of 50 PFU per cell by BVs alone, BV encapsulated in peptide–
DNA fiber, or BV simply mixed with the same amount of peptide and DNA used to 
form the fiber. The encapsulation was performed at a BV and DNA volume ratio of 
1:3. Fiber was drawn using 5 μL droplets of both peptide solution and BV plus 
plasmid solution. Fibers were deposited on a 24-well cell culture plate. Naked, fiber-
encapsulated, and mixed BVs were pre-treated with human serum complement at 
37°C for 30 minutes. 100 μL of human serum complement was used to inactivate BV, 
fiber, and the mixture. After serum treatment, cell culture media containing U87 cells 
were added on top of the fiber solution, making the final volume in each well 2 mL 
and therefore the final serum complement concentration 5%, to minimize the 
cytotoxic effect of human serum complement on U87 cells. EGFP and luciferase 
reporter gene expression was detected 48 hours post-transduction with the BV 
construct CMV-EGFP and CMV-Luc, respectively. (a) Fluorescence microscope 
images and flow cytometric analysis of EGFP-positive U87 cells 2 days after 
transduction. The percentages of EGFP-positive cells are indicated. FACS analysis 
was used to quantify the transduction efficiency of BV vectors. After trypsinization to 
detach U87 cells from the cell culture plate, the cells were collected, washed in PBS, 
and resuspended in PBS before being analyzed with a FACSCalibur Flow Cytometer. 
(b) Luciferase expression profiles of U87 cells 2 days after transduction. Luciferase 
expression is expressed as RLU per mg of total protein and the standard deviation is 
indicated with error bars (n = 5). BV, baculovirus; CMV-EGFP, cytomegalovirus-
enhanced green fluorescent protein; EGFP, enhanced green fluorescent protein; 
FACS, fluorescence-activated cell sorting; Luc, luciferase; MOI, multiplicity of 
infection; PBS, Phosphate Buffered Saline; PFU, plaque-forming units; RLU, relative 
light unit. 
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3.3.4 Therapeutic Efficiency of Bio-microfiber 
We performed additional studies to evaluate the inhibitory effect on tumor 
cells of the fiber encapsulating a BV carrying therapeutic genes. Inspired by 
the finding of selective expression of the HSV-TK suicide gene in glioma cells 
under the control of the HMGB2 promoter, we set out to examine the cellular 
effects of BV transduction for a duration of 24 hours followed by prodrug GCV 
treatment on U87 cells for another 24 hours. We constructed HMGB2-TK-BV 
to determine whether introduction of the HSV-TK gene would render U87 cells 
susceptible to induced cell death by GCV. This recombinant BV was used to 
transduce U87 glioma cells in culture. Various transduction complexes were 
then fabricated, including AR20-plasmid fiber encapsulating HMGB2-TK-BV 
and designated combinations of the three components, followed by treatment 
with human serum complement or PBS control. We then carried out cell 
viability analysis of U87 glioma cells, transduced by the above prepared 
transduction reagents, and of naked BV, using quantitative MTS assays. We 
found no obvious difference in the reduced viability caused by the induced cell 
death in glioma cell lines following GCV treatment, or after transduction in the 
absence of treatment with human serum complement (Figure 3.4A). However, 
in the presence of human serum complement, transduction of tumor cells by 
HMGB2-TK-BV fiber significantly reduced the number of viable U87 glioma 
cells at a GCV concentration of 500 μmol/L, whereas transduction by naked 
BV vectors produced no observable effect on U87 glioma cells at the same 
GCV level, suggesting fiber formation provides a barrier preventing the 
inactivation of HMGB2-TK-BV by human serum complement (Figure 3.4A). 
Furthermore, the tests indicated that only by establishing fibrous structure can 
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BV become resistant to serum complement inhibition. In the presence of 
serum complement, other combinations of transduction reagents failed to 
drive sufficient transgene expression of HMGB2-TK genes to induce the 
corresponding cells death achieved by the fiber group (Figure 3.4A). 
Collectively, the protective effect of fiber on BV is applicable for reporter genes 
and also for therapeutic genes such as HSV-TK. 
 
3.3.5 Tumor Suppressive Effect of Bio-microfiber 
After substantiating the superior efficiency of BV-encapsulating fiber in 
eliminating U87 glioma cells in vitro, we then explored the in vivo efficacy of 
the bio-microfiber. We studied the therapeutic efficacy of BV-mediated HSV-
TK gene delivery into U87 glioma cells followed by GCV administration in 
tumors generated on the backs of nude mice. We established glioma 
xenografts in nude mice using U87-Luc cells, followed by double injections of 
the designated gene transfer vectors into the xenografts on day 7 and day 14, 
respectively, post-tumor inoculation. Subsequently, GCV was administered by 
intraperitoneal injection daily for 2 consecutive weeks. During this period, we 
assessed tumor growth by determining the luciferase expression levels in 
tumor cells. Bioluminescence intensities from U87-Luc cells, indicative of 
tumor volume, were measured at 4-day intervals after tumor inoculation using 
a non-invasive in vivo imaging system. At days 11 and 19, there was an 
apparent slow-down in the speed of tumor growth in mice injected with fiber 
encapsulating HMGB2-TK-BV, probably due to the tumor suppression 
resulting from ample therapeutic gene expression. By contrast, an increase in 
tumor size was evident in the other control groups, suggesting that the tumor-
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killing effect of BV encapsulated in fiber is much better than that of naked BV 
and other gene delivery vector combinations (Figure 3.4B,C). Although the 
TK-induced suicide gene expression did not completely eliminate tumors in 
the mice, the fiber group showed activity high enough to inhibit in vivo tumor 
growth compared with BV alone, BV-AR20-plasmid mixture, and PBS groups. 
The luciferase quantification result was also supported by tumor size 
measurement data, showing a smaller tumor size in the fiber-injected mice at 
day 60 (Figure 3.4D). More importantly, survival data showed that by the end 
of the study, more mice survived the tumor inoculation in the fiber group, 
suggesting that the therapeutic efficacy of fiber-encapsulating BV is much 
more significant than in the other three groups (Figure 3.4E). These results 
demonstrated that the recombinant BV vector encapsulated in IPC fiber can 
function as an efficient gene delivery vehicle for the treatment of gliomas by in 
vivo gene therapy. 
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Figure 3.4 - Tumor inhibitory effect of bio-microfiber encapsulating HMGB2-TK-
BV. (a) Cell viability analysis of HMGB2-TK-BV–transduced U87 glioblastoma cells 
using quantitative MTS assays. BV containing an HMGB2-TK construct were 
employed to form complex or fiber with plasmid DNA and AR20 peptide using the 
same ratio as previously described. Cells were transduced for 24 hours with BV-TK, 
BV-TK+pDNA, BV-TK+AR20, BV-TK+pDNA+AR20, and BV-TK in AR20 fiber at an 
MOI of 50, followed by treatment with the prodrug GCV 500 μmol/L for another 24 
hours. Cell survival rates were then measured by MTS assay (Promega) following 
the manufacturer’s instructions. Cells were seeded onto 96-well plates at 1 × 104 
cells per well in DMEM supplemented with 10% FBS and infected with BVs. The 
spectrophotometric assay for cell proliferation was performed 24 and 48 hours later 
by measuring OD at 490 nm. For in vivo study, human glioma U87-Luc cells were 
inoculated into the back region of nude mice. After the tumor became visible, naked 
HMGB2-TK-BV, fiber encapsulating HMGB2-TK-BV, PBS, and a mixture containing 
HMGB2-TK-BV, plasmid DNA, and AR20 peptide, were injected into tumor xenografts 
on day 7 and day 14 post-tumor implantation, respectively. GCV (5 mg/mL) 
intraperitoneal injection was performed daily from day 8 to day 20. (b) IVIS 
bioluminescence images of tumors. Photos were taken non-invasively on day 7 and 
day 19 post-tumor cell inoculation, respectively, using the IVIS imaging system. (c) 
Quantitative analysis of tumor burden from IVIS bioluminescence images. The data 
are presented as the mean of tumor burden ± SD from 10 mice per group imaged 7 
and 19 days post-tumor cell inoculation. (d) Tumor size measurements of nude mice 
treated with bio-microfiber. Tumor size was measured by a caliper and calculated as 
0.5 x width2 x length and shown as cm3 at day 60. (e) Prolonged survival of mice 
treated with various gene delivery reagents containing HMGB2-TK-BV. The mice 
were observed until 60 days post-tumor inoculation. The significance was determined 
by the two-factor analysis of variance with replication followed by ANOVA analysis 
using SigmaStat 3.1 software. The statistical analysis of survival data was performed 
using the log rank test. A P<0.05 was considered statistically significant. BV, 
baculovirus; DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, fetal bovine serum; 
GCV, ganciclovir; HMGB2, human high-mobility group box 2; Luc, luciferase; MOI, 
multiplicity of infection; PBS, Phosphate Buffered Saline; TK, thymidine kinase. 
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Microfiber structure is one of the most extensively studied synthetic polymer 
biomaterials currently employed in tissue engineering and regenerative 
medicines (Sarkar et al., 2006). Polymeric materials are often modified to 
advance their desired biological activities through chemical reactions, coating, 
or encapsulation with biologics. However, this approach is rarely applied in 
cancer therapy through gene delivery, which requires effective transgene 
expression to kill tumor cells, even though several groups have demonstrated 
the possibility of accomplishing tumor inhibition by co-delivery of various 
polymer structures and drugs. In terms of treating brain tumors， researchers 
have developed several promising pre-clinical combined drug–polymer 
implants, including biodegradable 5-flurouracil-loaded microspheres, 
carboplatin-loaded PLGA microspheres, biodegradable PLGA polymer sheets, 
and aclarubicin-loaded cationic-albumin pegylated nanoparticles (Lu et al., 
2007; Menei et al., 1996; Chen and Lu, 1999). The development of drug 
resistance has been a major hindrance to the successful application of such 
drug delivery methods. This limitation, however, has led to the evolution of 
other polymer-mediated cancer therapies. For example, it was reported that 
paclitaxel-loaded biodegradable PLGA microfiber implants can effectively 
deliver paclitaxel for post-surgical chemotherapy against malignant glioma, 
and can mediate the sustained release of paclitaxel from fiber matrices 
(Ranganath and Wang, 2008). This discovery shed light on the application of 
microfiber in drug and gene delivery therapies for glioma, especially by means 
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of gene therapy where genetic composition can be tailored to fundamentally 
correct tumor pathogenicity. 
 
This study has provided evidence for the first time that microfiber assembly 
can significantly improve the transduction and therapeutic efficiency of BV-
based gene transfer vectors in glioma cells, both in vitro and in vivo. Effective 
gene delivery to tumor cells is essential for genetic treatment of CNS diseases 
such as glioma. It has been well established that BV as a novel gene transfer 
vector can transduce a number of mammalian cell lines, with satisfactory 
transduction efficiency and a bio-safety profile free from apparent viral 
replication or cytopathic effects (Boyce and Bucher, 1996). No viral replication 
or transcription of the BV genome has been detected in mammalian cells. 
Despite these encouraging advantages, however, one of the most challenging 
obstacles to the successful application of BV vectors has been its poor in vivo 
performance due to the vulnerability of BV to serum complement factors 
presented in the blood stream after systemic administration (Hofmann and 
Strauss, 1998). BV-mediated gene transfer has also been hampered by serum 
complement in organs in direct contact with complement components. This 
fact was corroborated by our in vitro transduction experiment in the presence 
of both human and mouse serum complement (Figure 3.5). In this study, we 
identified an innovative material engineering approach to overcome the 
problem of serum complement inactivation, thereby furthering the potential 
applications of BV vectors for genetic treatment of CNS diseases. 
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Figure 3.5 - Effect of human and mouse serum concentration on BV 
transduction efficiency. Human U87 glioblastoma cells were used. Cells were 
transduced by BVs at an MOI of 50 PFU per cell. Naked BVs were pre-treated with 
serum complement at 37°C for 30 minutes. 100 μL serum complement was used to 
inactivate BV, fiber, and the mixture. The serum complement concentration range 
from 0 to 50% was achieved by adjusting the BV solution volume while keeping the 
BV copy number constant. After serum treatment, cell culture media containing U87 
cells were added on top of the BV and serum mixture, making the final volume in 
each well 2 mL and therefore the final serum complement concentration 5%, to 
minimize the cytotoxic effect of serum complement on U87 cells. (a) Luciferase 
expression profiles at various serum concentrations. Luciferase assay was performed 
24 hours post-transduction on U87 cells transduced with CMV-Luc BV. The results 
are shown as mean RLU of luciferase activities per mg of cellular protein (mean ± SD, 
obtained from five replicate assays). Percentage of reduction in BV transduction 
efficiencies is indicated. (b) EGFP expression profiles at various serum 
concentrations. The cells transduced with CMV-EGFP BV were photographed under 
fluorescent microscope 24 hours after transduction. BV, baculovirus; CMV, 
cytomegalovirus; EGFP, enhanced green fluorescent protein; Luc, luciferase; MOI, 
multiplicity of infection; PFU, plaque-forming units; RLU, relative light unit. 
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We further examined the mechanism by which microfiber encapsulation can 
protect BV against serum complement inactivation, and achieved enhanced 
transduction efficiency with fiber-encapsulated BV. Since the size of most 
mammalian cells is comparable to these microfibers (10–100 μm), upon 
attachment to the microfibers the cells still exhibit a 3D topology with a 
curvature that depends on the compatibility of the dimensions of the cells and 
microfibers. Because of their microscale sizes, the mechanical strength of the 
fibers usually prevents further material structural alteration as a result of the 
forces exerted by cells during the adhesion, migration, and transduction 
processes. We incorporated BV particles in the microfiber assembled through 
charge attraction between condensed peptide and plasmid DNA electrolyte 
solutions, with an encapsulation efficiency of 68% (Table 3.1). Since fibers 
both with and without BV encapsulation dissolve slowly in cell culture medium 
(up to 10 hours) (Figure 3.6), we reasoned that the fibers would shield the 
virus for a certain period of time. Many peptides with a standard amphiphilic 
binary pattern easily aggregate to form bundles or gels of assembled 
structures displaying varying morphologies. The broad hydrophobic or 
charged faces of the peptides offered the possibility for varied interfacing and 
intermolecular arrangements with DNA, allowing the formation of a range of 
microfibers. The interactions appeared to form nanofiber intermediates, and 
further bundled and formed a network towards a microfiber architecture. 
Rheology measurements revealed that the viscosity of the peptide and 
plasmid mixture increased exponentially after being blended together, 
indicating the possible formation of polyelectrolyte complex and possibly 
nanofibers among these two components (Figure 3.7). This finding, coupled 
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with the fact that plasmid retains its functionality after forming fiber with 
peptide (Figure 3.8), further supports the supposition that the released virus 
may be still surrounded by peptide–DNA nanofibers or fragments assembled 
from the active DNA and peptide, which need to be degraded extracellularly or 
even intracellularly before gene expression can reach its peak. We illustrated 
that the virus does not show any significant loss in activity in the 
encapsulation process. In addition, we noticed that there was no new 
chemical bond formed during the fiber formation process (Figure 3.9), 
suggesting the main driving force behind fiber formation is electrostatic 
interaction. Based on these characterization studies, we speculate that the 
underlying mechanics of the protection of fibers against serum inactivation is 
that fibrous matrices not only mediate controlled and sustained release of BVs 
into the media as the fiber dissolves, but also provide greater surface area to 
volume ratio for effective BV release rates directly to the cells attached to the 
fiber. Even after being released into the serum-containing media, the BV 
particles may still be coated or bound by the peptide–DNA nanofibers or 
peptide molecules alone, which on their own have already shown some ability 
to protect BV from serum inactivation (data not shown). Conversely, free BV 
particles are completely exposed to the serum-containing media during the 
diffusion process, a major means by which BVs approach the cell surface, 
and transduction activity is easily inhibited by the complement factor unless a 
system of shielding, timed releasing, or protective tagging is employed. 
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Sample Ct/Mean SQ Mean Total BV copy number 
Original BV 15.52 1.12E+07 4.13E+08 
Fiber 15.51 1.13E+07 2.81E+08 
Leftover 16.70 5.30E+06 1.32E+08 
Encapsulation 
efficiency 68%   
 
Table 3.1 - BV encapsulation efficiency of fiber. Fiber containing CMV-Luc-BV was 
produced as previously described. Immediately after the fiber was fabricated, both 
the fiber and the leftover mixture were dissolved in 200 µL cell culture media followed 
by copy number measurement by Real-Time quantitative PCR. Encapsulation 
efficiency is calculated as BV copy number in fiber divided by total BV copy number 
used to form fiber. BV, baculovirus; CMV, cytomegalovirus; Luc, luciferase; PCR, 
polymerase chain reaction. 
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Figure 3.6 - Solubility of AR20 fibers without or with BV encapsulation. Photos 
were taken under light microscope showing AR20-DNA fiber morphology (left panel) 
in DMEM cell culture media containing 10% FBS and 1% penicillin-streptomycin at 0, 
5, and 10 hours, respectively. Photos in the right panel show the morphology of 
AR20-DNA fibers encapsulating BV under the same conditions at 0, 5, and 10 hours, 
respectively, suggesting fibers both with and without BV encapsulation were 
degraded and dissolved within 10 hours. The fibers were viewed under a 
transmission microscope at 4x magnification. BV, baculovirus; DMEM, Dulbecco’s 
Modified Eagle’s Medium; FBS, fetal bovine serum. 
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Figure 3.7 - Rheological properties of the raw materials used to form fiber. Fiber 
formation was performed using an 8 µg/µL AR20 peptide solution and 8 µg/µL 
plasmid DNA solution. The two solutions were mixed together with a 1:1 volume ratio 
to form the pDNA+AR20 mixture solution used for viscosity measurements. 
Meanwhile, a plasmid DNA solution was mixed with a concentrated BV PBS solution 
with the titer of 109 PFU per mL using a volume ratio of 3:1 to constitute the 
negatively charged polyelectrolyte solution. This mixture was then mixed with the 
AR20 peptide solution noted above with a 1:1 volume ratio, after which viscosity 
measurements were performed with a RheoScope 1 rheometer. BV, baculovirus; 
PBS, Phosphate Buffered Saline; PFU, plaque-forming units. 
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Figure 3.8 - Luciferase gene expression profiles of plasmid DNA in fibers and 
mixtures. Transfection efficiencies of plasmid DNA before and after the formation of 
fiber. Human U87 glioblastoma cells were used. For the lipofectin group, 10 μg of 
DNA was diluted in 100 μL of Opti-MEM I Reduced Serum Medium followed by the 
dilution of 10 μL of Lipofectin in 100 μL of Opti-MEM I Medium. The solutions were 
left to stand at room temperature for 40 minutes, after which the diluted DNA was 
combined with the diluted Lipofectin (total volume = 200 μL). The solution was mixed  
gently and incubated for 15 minutes at room temperature. For the fiber groups, 10 μg 
of DNA was used to form fiber with peptide or peptide and BV using the same ratio 
as previously described. For the mixture groups, the same amount of plasmid DNA 
was mixed with the amount of peptide or peptide and BV used previously to form the 
fiber. U87 cells were transfected into 24-well plates per cell by pDNA, pDNA+AR20, 
pDNA+AR20+BV-GFP, pDNA/AR20 fiber, pDNA/AR20/BV-GFP fiber, and pDNA+ 
Lipofectin. Cells were cultivated in the growth medium for 24 hours before the 
luciferase assay. The results are shown as the mean RLU of luciferase activities per 
mg of cellular protein (mean ± SD, obtained from five replicate assays). BV, 
baculovirus; GFP, green fluorescent protein; Lip, Lipofectin; RLU, relative light unit. 
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Figure 3.9 - NMR spectrum of peptide, plasmid DNA, and peptide–DNA fiber. 
Fiber was formed as previously described using 8 µg/µL AR20 peptide solution and 
8 µg/µL plasmid DNA solution. The same solutions were used to carry out the NMR 
measurements. All samples were prepared by dissolving about 10 mg of materials in 
1 mL D2O. The 1 hour NMR was performed with a Bruker DPX-300 NMR 
Spectrometer. D2O, deuterium oxide; NMR, nuclear magnetic resonance. 
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Another hallmark of our findings is the suppressive effect of HMGB2-TK-BV-
containing microfiber on subcutaneously inoculated tumors compared with the 
naked BV in nude mice. Malignant glioma, known as glioblastoma multiforme, 
is characterized by aggressive ontogenesis of undifferentiated cells, pervasive 
invasion into nearby brain tissue, and a high percentage of recurrence, and is 
therefore one of the most refractory tumors. Although most glioma patients 
have access to state-of-the-art imaging, neurosurgery, radiotherapy, and 
chemotherapy, the median survival time is around 3 months and most patients 
fail to live more than 3 years post-diagnosis (Ohgaki et al., 2004; Ohgaki and 
Kleihues, 2005). Recent advancements in molecular biology and gene 
therapy have provided the tools to treat patients with malignant brain tumors 
by modifying the gene expression profiles in tumor cells. Virus-mediated 
transfer of the HSV-TK gene has been commonly employed to present 
cytotoxic sensitivity to nucleoside analogues, such as GCV, in a wide 
spectrum of tumor cells both in vitro and in vivo (Moolten, 1986). HSV-TK 
protein functions by converting the prodrug GCV into a phosphorylated 
compound that selectively defeats dividing cells by acting as a chain 
terminator in DNA synthesis. This approach is particularly suitable for 
treatment of glioma tumors, which grow aggressively and invade normal brain 
tissue, consisting largely of non-proliferating cells. Recombinant retroviral 
vectors containing HSV-TK have been successfully generated and used to 
confer significant regression of tumors originated from inoculating glioma cells 
in rat brains (Culver et al., 1992). Tumor development and progression 
engage alterations in a variety of genes; therefore, a variety of BV-based gene 
delivery approaches for malignant gliomas have been established. The 
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recombinant BV vector has been used extensively to achieve high levels of 
transduction efficiency and transgene expression in cultured mammalian cells 
and in experimental animal models. Attempts have been made to 
experimentally treat glioma by systemic injecting of PEI-coated BV vectors in 
a nude mice xenograft model, and the resulting binary complex is resistant to 
serum complement inactivation when compared with naked BV (Yang et al., 
2009). On the other hand, based on the observation that the HMGB2 
promoter is capable of inducing glioma-specific gene expression, targeted 
cancer therapy has been realized by using a BV vector expressing the HSV-
TK suicide gene driven by the HMGB2 promoter (Balani et al., 2009). 
 
Encouraged by the findings in previous studies, we hypothesized that the 
microfiber complexation methodology may offer the possibility of 
circumventing the serum inactivation problem faced by BV vectors in vivo. We 
investigated the capacity of a hybrid BV-fiber vector to produce a high level of 
transduction and gene expression of HSV-TK under the control of the HMGB2 
promoter, and to render U87 glioma cells vulnerable to the cytotoxic effects of 
phosphorylated GCV. Polyelectrolyte fibers were formed by drawing two 
droplets of peptide and plasmid DNA plus therapeutic BV solution together, 
and glioma xenografts were established in nude mice using U87-Luc cells, 
followed by double injections of the designated vectors into the xenografts at a 
1-week interval. As expected, there was an obvious lag in the speed of tumor 
growth in the mice injected with fiber-encapsulated HMGB2-TK-BV as 
compared to the naked HMGB2-TK-BV and other control groups. This 
suggests that local recurrence of the tumor is controlled and inhibited by the 
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sustained release of therapeutic BV vectors from the protective fiber, 
preventing them from being inactivated by serum complement factors being 
present in the vascularized tumor tissues. This finding is further confirmed by 
the smaller local glioma size observed is the groups treated with fiber-
encapsulated BV, as well as an increased survival rate in the fiber group. 
Thus, by inhibiting local recurrence possibly induced by complement 
inactivating effect of the surrounding blood serum, improvement in patient 
survival seems achievable. 
 
Conclusion 
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4.1 Results and Indications 
The objective of this study was to establish safe and efficient gene delivery 
systems with the objective of significantly improving the gene transfer 
performance for neurological disorders in the CNS, particularly glioma tumors. 
This study can be divided into two parts: establishing both DNA-based and 
BV-based bio-nanoparticles, and developing bio-microfibers for BV 
encapsulation.  
 
4.1.1 Generation and Assessment of Bio-nanoparticles 
While both magnetic field-mediated gene transfer and Tat peptide-assisted 
delivery offer attractive therapeutic features, this study has documented that 
the two methods combined provide additional advantages in improving 
targeted transgene expression. We believe this strategy holds potential for 
gene therapy applications, especially those that require targeting approaches 
for effective localized treatment. Gene delivery using PEI involves 
condensation of DNA into compact particles, uptake into the cells, release 
from the endosomal compartment into the cytoplasm, and uptake of the DNA 
into the nucleus. This multistep process indicates that there are many factors 
affecting the transfection efficiency of PEI-based gene delivery vectors, 
including particle size, molecular weight, shape (branch or linear), and surface 
charge. The magnetic nanoparticles used in this study were coated with PEI 
25 kDa; therefore, the gene transfer route was expected to resemble that 
mediated solely by PEI. We intended to accelerate the cell uptake process by 
applying an external magnetic force during the transfection process and then 
expediting the endosomal escape step by tagging the vector with Tat peptide. 
Conclusion 
                                                                                                                      
 117 
In this way, the traditional PEI vector was multifunctionalized to achieve 
enhanced transfection efficiencies. 
 
Gene therapy holds promise in treating neurological disorders such as glioma, 
but is still in the pre-clinical trial phase. One of the most challenging obstacles 
to successful clinical application is the difficulty in achieving efficient gene 
delivery to the brain due to the blood–brain barrier. The bio-nanoparticle 
system developed in this study could potentially provide an innovative 
engineering approach to this problem. We used lumbar injection, a low 
invasive procedure, to circumvent the blood–brain barrier for efficient gene 
expression in the spinal cord. However, only limited distribution of gene 
expression can be observed in the CNS, probably due to CSF flow, which 
poses a restriction on the use of this technique for the treatment of CNS 
disorders. 
 
One of the most promising features of bio-nanoparticles is their ability to 
target the genes in special organs or tissues in the presence of an external 
magnetic force. This study showed the potential of magnetofection to deliver 
genes to desired sites in the CNS using external magnetic fields. During the 
animal study, we found an external magnet could be used to manipulate the 
distribution of gene transfer vectors along the spinal cord. Under magnetic 
guidance, bio-nanoparticles were forced to accumulate in the cervical region 
of the spinal cord as indicated by the gene expression patterns, suggesting 
this modular approach can be practically used to overcome the blood–brain 
barrier. Future studies could focus on the in-depth development and 
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optimization of such retargeting platform technologies to circumvent current 
barriers to glioma gene therapy. In addition, new magnetic guiding systems 
need to be designed and optimized to produce suitable magnetic forces for 
use in human gene therapy. 
 
We found that the transduction efficiency of BV-based bio-nanoparticles was 
substantially higher than that achieved by naked BV when magnetic force was 
applied, an indication that gene delivery performance in a serum-containing 
environment could be greatly improved by forming bio-nanoparticles with 
PolyMag. Moreover, our results suggested that the magnetic force played an 
important role in enhancing the luciferase expression of the PolyMag-BV 
complex. Results obtained in the absence and in the presence of external 
magnetic force during transduction in a serum-containing medium indicated 
the multifunctionality of the PolyMag-BV bio-nanoparticles to simultaneously 
achieve magnetically guided transduction and the protection of BV against 
serum complement inactivation. 
 
We used human glioma cell lines and animal models of human gliomas to 
investigate the gene delivery efficiency and therapeutic efficacy of the 
developed bio-nanoparticles. We employed mainly reporter genes such as 
EGFP and luciferase to characterize our designated modular gene delivery 
systems. For future studies, it would be useful to customize the complex 
forming parameters and transfection or transduction conditions for the 
therapeutic genes when designing more complicated gene transfer vectors for 
clinical application. We expect the knowledge gleaned from this project could 
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be valuable in developing effective and potent delivery vectors not only for 
gene therapy of gliomas, but also for other types of tumors. In addition, when 
dealing with other relevant plasmid DNA or virus complex vectors, the 
production procedures and characterization methods should be optimized 
according to the unique features of specific vector constructs. 
 
4.1.2 Assembly and Evaluation of Bio-microfibers 
We established a method to form bio-microfibers through self-assembly of 
polyelectrolytes comprising plasmid DNA and amphiphilic and Tat peptides, 
and used the fibers to encapsulate BV particles to protect the viruses against 
serum complement inactivation. The suicide gene-mediated glioma therapy 
could be accomplished by BV carrying HSV-TK under the control of the 
glioma-specific HMGB2 promoter, followed by systemic administration of the 
prodrug GCV. However, the efficacy of this approach is often undermined by 
serum complement inactivation of the BV, resulting from angiogenesis and 
pre-existing blood vessels present in tumor tissues, which makes it extremely 
difficult to achieve sufficient suicide gene expressions within gliomas. We 
demonstrated that BVs retain their activity in the presence of human serum 
complement after being encapsulated in the fiber. More importantly, the 
incorporated BV vectors were found to be functional in suppressing the 
aggressive growth of human brain tumor xenografts in nude mice. The 
HMGB2-TK-BV–based bio-microfibers were shown to effectively induce cell 
death in the presence of GCV. A luciferase reporter gene expressing human 
glioma cell line (U87-Luc) in the xenograft animal model was established in 
this study, allowing for non-invasive monitoring of glioma growth in vivo. High 
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transduction efficiency was observed in U87 cells in vitro, when transduced by 
HMGB2-TK-BV–based bio-microfibers pre-treated with human serum 
complement. Thus, it is reasonable to expect a significant suppression of U87 
cell growth in similar animal models. Even though the U87 cells were not 
completely eliminated by the HSV-TK gene expression, probably due to the 
poor diffusion of injected bio-microfibers within the tumor mass, the gene 
delivery efficiency of bio-microfibers was high enough to inhibit tumor growth 
when compared with naked BV and other unprotected viral vectors. To 
improve delivery efficiency, we attempted to implant the bio-microfiber inside 
the glioma xenografts in nude mice. The overall gene expression level in the 
entire tumor mass was not increased, although local expression along the 
implantation site appeared elevated. Therefore, it is necessary to further 
enhance the inhibitory effect of such bio-microfibers by either injecting fiber 
solutions into several sites of the glioma mass, or optimizing delivery 
protocols in the pre-clinical study. The current proof-of-principle study has 
provided gene therapeutic strategies to overcome one of the most challenging 
issues still outstanding for clinical application of BV-mediated gene therapy in 
malignant gliomas. In this study, the therapeutic efficacy of bio-microfibers 
was tested only in human glioma cell line xenograft models. Further research 
could also involve tumors generated by stereotaxic intracerebral injection of 
human glioma cells in nude mice for more clinically relevant results. Thus, the 
gene delivery systems developed in this study hold great potential for gene 
therapy of disorders in the CNS. 
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4.2 Conclusion 
With hybrid non-viral and viral vectors, this study provides useful delivery 
systems for gene therapy of disorders in the CNS. In this study, to develop 
efficient gene delivery systems for CNS disorders, especially glioma, we 
investigated DNA and BV-mediated gene delivery systems by modification or 
combination with other materials such as nanoparticles and microfibers. We 
also tried to apply them in a CNS disease model—glioma tumors—both in 
vitro and in vivo to explore the possibility of their application in human gene 
therapy. Efficient and site-specific gene delivery to the CNS is critical for the 
success of gene therapy to achieve satisfactory therapeutic effects. We 
successfully generated the magnetic complexes for efficient gene transfer in 
vitro by incorporating Tat peptides with PolyMag/DNA. We also demonstrated 
the possibility of assembling bio-nanoparticles using BV and PolyMag, and 
their efficient in vitro gene delivery performance in preventing serum 
complement inactivation. This study documented that magnetically guided 
gene delivery can conquer the distribution confinement of gene agents 
intrathecally injected in the CNS. Therefore, the combination of 
magnetofection and the spinal fluid delivery technique hold significant 
potential to effectively delivery therapeutic genes to the CNS for the treatment 
of glioma, spinal cord injury, and other degenerative neurological illnesses. In 
addition, we illustrated that microfiber structures could be formed by self-
assembly of concentrated peptide solutions and plasmid DNA solutions 
through electrostatic interaction. Numerous advantages highlight the newly 
emerged BV as one of the most promising gene delivery vectors. Such fibers 
could be used to encapsulate BV for the purpose of protecting it against 
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serum complement inactivation presented during systemic administration. The 
BVs incorporated in the microfiber were found to be resistant to serum 
complement inhibition. Moreover, bio-microfibers encapsulating therapeutic 
BVs were discovered to suppress tumor growth in human glioma cell line 
xenograft animal models, indicating the strong clinical application potential of 
such technology. 
 
The procedures and findings presented in this thesis involve the preparation, 
characterization, and assessment of the transduction efficiency and 
therapeutic efficacy of two gene delivery systems: plasmid DNA or BV-based 
bio-nanoparticles and BV-based bio-microfibers. Our findings suggest these 
delivery systems are efficient both in vitro and in vivo, and their applications in 
glioma models indicate their promising future in clinical glioma therapy, 
although further improvements and modifications are needed for optimal 
therapeutic effect. To the best of our knowledge, this study is the first 
demonstration of the use of microfiber structures to protect BV against serum 
complement inactivation and the use of such vectors for cancer gene therapy 
in an animal model. We believe our results will provide important insights for 
potential human clinical trials. Due to the disappointing outcomes of clinical 
trials in current glioma gene therapy, it is crucial to establish efficient gene 
delivery vector systems that can be safely adopted in the clinical setting. The 
knowledge generated from these experimental results, such as the 
development of complex gene transfer vectors and the evaluation of relevant 
complexation methodologies, should greatly assist the exploration and 
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establishment of CNS gene therapies as well as the promotion of BV-related 
and gene therapy-related fields.  
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